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1. Abstract 
 
Hypoxia, low glucose and low pH characteristics of tumor microenvironment are associated with 
a condition known as ER stress and, consequently, Unfolded Protein Response activation. Cancer 
cells are capable to survive in various hostile environments. For instance, they have developed 
many strategies to take advantages from adverse conditions, present in tumor tissue, by using 
specific activities of oncogene and mutated proteins. One of the most highly mutated gene in 
human cancer is the P53 gene. By analyzing expression profile of five different cancer cells 
bearing mutant p53, we, interestingly, observed, upon depletion of mutp53, an enrichment on 
global Unfolded Protein Response (UPR) genes. This finding suggest that mutant p53 might have 
an effect in controlling UPR. In particular, we hypothesized that mutp53 is reprogramming UPR 
to sustain cancer cells survival. To test this hypothesis, we, firstly, analyzed whether cancer cells 
bearing mutant p53 were more resistant to treatment with ER stress inducers: Thapsigargin (Tg) 
and Tunicamycin (Tm). Then, by analyzing the three main mediators of UPR (IRE, PERK and ATF6) 
and their downstream effectors, we observed that mutant p53 is dampening pro-apoptotic 
pathways of UPR, CHOP and JNK, and it is, also, promoting ATF6 transcriptional activity. Since 
ATF6 is crucial for protein quality control and chaperones production, we hypothesized that 
mutp53 is using ATF6 transcriptional activity to resolve the stress. Interestingly, we observed that 
ATF6, as well mutant p53, is crucial for cancer cells survival, but, surprisingly, not only upon ER 
stress induction. We further confirm these observations by using specific inhibitors of ATF6, 
confirming its pro-survival functions. Finally, we used these findings to test whether, 
concomitantly inhibition of mutant p53 and ATF6, could represent a promising strategy for 
cancer treatment. Taken together our data proposed a novel oncogenic function of mutant p53 
in the promotion of cancer cells survival and in maintenance cancer cells homeostasis. 
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2. Introduction 
 
2.1 TP53 and cancer 
Cancer, nowadays, represents the major cause of death worldwide. Gene mutations are 
necessary to induce neoplastic transformation and interest both onco-suppressors and 
oncogenes.  
One of the most highly mutated genes in human cancer is TP53. The P53 protein was first 
discovered in 1979 (DeLeo et al., 1979) and its role in cancer has become increasingly important 
in recent years.  
 
P53 is one of the most important players in the response to many types of stress that can lead to 
loss of genomic integrity and cancer development (Kastan et al. 1991; Vogelstein et al. 2000). 
P53 responds at these stresses inducing irreversible senescence and consequently apoptosis 
(Figure1) (Yonish-Rouach et al. 1991; Serrano et al. 1997).  
Nevertheless, apoptosis or permanent senescence could compromise organism survival 
suggesting that p53 activity needs to be tightly regulate. Accordingly, to this, in cells exist a large 
number of mechanisms that control p53 activity. The most important is mediated by Mdm2, an 
ubiquitin ligase, which regulates p53 through a negative feedback loop: p53 activates 
Figure 1: Deconstructing p53 transcriptional networks in tumor suppression. (Attardi, 2012) 
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transcription of the mdm2 gene, whose protein product then targets p53 for ubiquitin-
dependent degradation (Freedman et al., 1999). Thus, any increase in p53 activity is accompanied 
by increased p53 degradation.  
Under genotoxic conditions, p53 protein levels are increased upon phosphorylation on Ser20 by 
the Chk2 kinase, this induces Mdm2 dissociation from p53. This process is under the control of 
the ATM protein kinase, which is activated in response to DNA DSBs, and play a key role in p53 
activation. A similar mechanism regulates the activation of p53 upon block of DNA replication 
and it is mediate by ATR, an ATM related kinase (Abraham 2001; Iliakis et al. 2003). Other 
mechanisms of regulation of p53 are numerous post-translational modifications as acetylation of 
several lysines that enhance p53 transcriptional activity by stabilizing p53 protein, blocking its 
degradation (Brooks and Gu 2003; Xu 2003). To summarize, p53 stability and transcriptional 
activity are finely regulated in cells that are exposed to various stress. 
 
2.2 Mutant p53 and its gain-of-function 
Mutations in the TP53 gene occur in many tumor types. In fact, about 70% of TP53 mutations are 
missense and occur in the region encoding the DNA binding domain (DBD) of the p53 protein; 
some are considered hotspot mutations that are frequently found both in sporadic and in 
hereditary tumors. DBD mutations induce changes in p53 conformation or prevent binding to 
DNA, blocking p53 transcriptional activity or altering its interaction with other proteins.  
Firstly, TP53 mutations inactivate the oncosuppressive properties of the wild-type p53 protein as 
a transcription factor – a phenomenon defined as loss-of-function (LOF). In addition, p53 mutant 
proteins can exert a dominant negative (DN) effect on the wild-type p53 allele in heterozygous 
conditions, as matter of fact tetramers that present both wt and mutp53 proteins are not 
functional. Finally, it is well established that mutant forms of p53 can acquire novel oncogenic 
activities, defined as gain-of-function (GOF) (Figure 2).  
In order to sustain tumor development, mutant p53 plays a role in multiple pathways and 
processes. For example, mutp53 is implicated in the direct inhibition of the p63/p73-mediated 
tumor suppression (Li and Prives, 2007). This also induces an increase of PDGFRb, normally 
inhibited by the p73/NFY complex. In fact, high levels of PDGFRb correlates with poor disease-
free survival in cancer patients (Weissmueller et al., 2014). Mutant p53 is also related with an 
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activation of cell cycle drivers, such as Cyclins or in the vitamin D3 receptor signaling (Stambolsky 
et al., 2010). 
Despite being incapable of sequence-specific 
DNA binding, mutant p53 has a strong impact 
on gene expression by interacting with several 
other transcription factors, modifying their 
activity, or promoting selective regulation of 
specific target genes (Walerych et al., 2015).  
For instance, under proteotoxic conditions, 
mutant p53 uses NRF2 transcriptional activity 
to induce antioxidant factors and to sustain 
cancer cells survival. Interestingly, in healthy 
conditions NRF2 inhibits transcription of some 
genes that, in tumor cells bearing mutant p53, 
appear to be crucial for sustaining survival and 
growth (Walerych et al., 2016). 
A similar mechanism involves Heat Shock Factor 1 (HSF1), that is directly bound by mutant p53. 
This binding facilitates the recruitment of HSF1 to its specific DNA-binding elements and 
stimulates transcription of heat-shock proteins including Hsp90. Sustaining, in this way, mutant 
p53 stabilization (Li et al., 2014).  
Being very stable, mutant p53 is present both in the nucleus and in the cytoplasm. This 
cytoplasmic localization gives to mutp53 the possibility to bind to and affect the functions of 
various proteins that normally do not interact with nuclear wild-type p53. For instance, mutp53 
can bind cytosolic AMP-activated protein kinase (AMPK), leading to inhibition of anabolic 
metabolism and activation of aerobic glycolysis, i.e. the Warburg effect (Zhou et al., 2014). 
Similarly, by binding the tumor suppressor DAB2IP in the cytoplasm, mutant p53 is able to block 
JNK phosphorylation and to activate the NF-kB pathway upon TNFa treatment, promoting an 
aggressive response to inflammation (Di Minin et al., 2014). The inhibition of DAB2iP by mutant 
p53 can also amplify AKT phosphorylation upon insulin treatment, sustaining tumor proliferation 
and invasion under conditions of hyperinsulinemia (Valentino et al., 2017). 
Mutant p53 can also sustain cancer progression by remodeling the extracellular matrix, inducing 
secretion of metalloproteases, and various pro-inflammatory and immunomodulatory cytokines. 
Figure 2: When mutants gain new powers: news from the mutant 
p53 field. (Brosh and Rotter, 2009) 
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In addition, by stimulating secretion of lactate, mutp53 induces extracellular acidification 
regulating the fine crosstalk between cancer and stromal cells (Cordani et al., 2016). 
Mutant p53 can also affect steroid biosynthesis, in particular by acting on the mevalonate 
pathway – this has a profound oncogenic impact, also mediated by activation of YAP/TAZ (Di 
Agostino et al., 2015) and ID4-regulated angiogenesis (Fontemaggi et al., 2009). 
More recently, it was discovered that mutant p53 promotes transcription of the ER localized 
enzyme ectonucleside triphosphate diphosphohydrolase (ENTPD5). This leads to stimulation of 
the calnexin/calreticulin-dependent quality control that could help cells to survive in proteotoxic 
conditions. Importantly, by upregulating ENTPD5 mutant p53 promotes N-glycosylation, folding, 
and maturation of secreted growth factors and membrane receptors, in turn enhancing cancer 
cell proliferation and/or survival (Vogiatzi et al., 2016).  
 
2.3 Targeting mutant p53 
 
Given its central role in cancer progression, invasion, and metastasis, targeting mutant p53 
function may reveal potential strategies to develop novel anti-cancer therapies (Figure 3).  
Considering that mutp53 stability is key to its GOF, one approach is to stimulate its degradation. 
As for wt p53, MDM2 seems to be a major determinant of mutant p53 levels. Therefore, 
specifically and selectively 
activating MDM2-induced 
degradation may be a strategy 
to eliminate mutant p53 
(Terzian et al., 2008).  
Mutant p53 is stabilized by 
interaction with the HSP90 
machinery, which includes 
HSP90, HSP70 and other co-
chaperones (Peng et al., 2001). 
This complex binds MDM2 and 
CHiP, blocking their capacity to 
induce mutant p53 degradation. Disruption of this complex or inhibition of chaperones activity 
in cultured cells, induces the release of MDM2 and CHiP from inhibition and triggered mutant 
Figure 3: Mutant p53 in cancer: new functions and therapeutic opportunities. (Muller 
and Vousden, 2014) 
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p53 degradation (Peng et al., 2001). Based on this knowledge, compounds that inhibit HSP90 
were proposed as strategy to impaired mutant p53 stability.  
As matter of fact, pharmacological inhibition of HSP90 ATP-dependent chaperone activity by 
Geldanamycin or 17AAG is able to reduce mutant p53 stability (Whitesell et al., 1998). Several 
HSP90 inhibitors were show to inhibit tumor growth in pre-clinical models and in patients, and 
some of them are in phase II clinical trials.  
Another class of compounds that reduce mutant p53 protein levels are the histone deacetylase 
inhibitors (HDACi). Interestingly, these compounds elicit different anticancer responses apart 
from destabilization of mutant p53. At least three HDACi have been reported to reduce mutant 
p53 levels in cell lines, FR901228, Trichostatin A (TSA) and suberoylanilide hydroxamic acid 
(SAHA), which however were proposed to act through different mechanisms (Wang et al., 2016). 
SAHA inhibits HDAC6, which normally activates HSP90 by promoting deacetylation of K294. Upon 
SAHA treatment, MDM2 and CHIP may be released from inhibition by HSP90 complex and induce 
mutant p53 degradation (Li et al., 2011; Wang et al., 2016). In contrast, the effects of FR901228 
and TSA on mutant p53 levels are accompanied by conformational changes in mutant p53 and 
transcriptional induction of p21 and MDM2, suggesting reactivation of wt-like p53 conformation 
(Bajbouj et al., 2012; Blagosklonny et al., 2002). 
It was shown that phosphorylation of mutant p53 on S15 and S37 contributes to protein 
stabilization and that the kinase responsible for these modifications is DNA-PK. Targeting DNA-
PK by NU7441 reduced mutant p53 phosphorylation on S15 and S37, suggesting a potential use 
in strategies aiming at inducing mutant p53 degradation (Sunada et al., 2016). Small molecules 
that directly modify mutant p53 promoting its transition into a wild-type like form, capable of 
activating the tumor suppressive wild-type p53 transcriptional targets, are also gaining attention. 
Great interest has been obtained by PRIMA-1 molecule (Teoh et al., 2016), and later by its more 
potent and less toxic derivative PRIMA- 1MET/APR-246 (Walerych et al., 2016).  This compound 
successfully went through phase I/II clinical trial in hematological malignancies and prostate 
cancer that included mutant p53 patients (Lambert et al., 2010).  
Finally, great interest was raised by evidences that glucose restriction affects mutant p53 
stabilization; cancer cell lines bearing mutant p53 showed a marked reduction on endogenous 
mutp53 levels when grown in conditions of glucose starvation, moreover compounds such as 
glucocorticoids, that target the mevalonate pathway, are also able to inactivate mutant p53 
(William et al., 2013; Parrales et al., 2016). Interestingly, whether on one hand pharmacological 
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manipulation of glucose metabolism may provide novel tools to induce mutant p53 degradation, 
through its deacetylation and ubiquitination (Sorrentino et al., 2017), on the other hand it 
suggests the exciting possibility that dietary regulation may help to restrain tumor progression in 
cases bearing mutant p53.  
In summary, pharmacological targeting of mutant p53 functions may have powerful implications 
for therapy; to this aim, a highly efficient strategy would be to simultaneously target both mutant 
p53 protein and its downstream activated pathways. 
 
2.4 The Endoplasmic Reticulum and secretory pathway 
 
The Endoplasmic Reticulum (ER) is a network of membrane-bound cavities permeating the entire 
cytoplasm from the cell membrane to the nucleus (Palade and Porter, 1954). The ER not only is 
the cradle of most lipids and of membrane and secreted proteins, but also is the major Ca2+ 
storage in the cell and a hub for signal integration (Meldolesi and Pozzan, 1998). Distinct sub-
regions of the ER have specialized tasks. In particular, contact sites with other organelles, such as 
mitochondria, are fundamental for signaling and lipid transfer. In order to maintain physiological 
and developmental needs, cells are able to adapt the size and functional capacity of the ER 
(Shibata et al., 2006).  
Secretory proteins in ER compartment acquire fundamental modifications such as N-
glycosylation, necessary for their maturation. One of the most important roles of the ER is helping 
protein folding, thanks to the presence of a large number of chaperones and a favorable 
environment. Newly synthesized proteins progressively adopt conformations that are 
energetically more favorable, until the correctly folded ‘native’ conformation is reached (Ellgaard 
and Helenius, 2003). Only when proteins are fully folded, all chaperones release and allow their 
exit to travel further along the secretory pathway. As such, stringent quality control is exerted on 
the secretory proteome. 
Once proteins are correctly folded, they have to exit from the ER lumen. Folding and assembly 
are fully completed when proteins arrive in the Golgi. In downstream compartments of the 
secretory pathway, N-linked glycans often are further modified in several ways (De Matteis and 
Luini, 2008). If immature client proteins exit the ER, they are retrieved through retrograde 
transport. The ER chaperones and foldases in small numbers do travel to the Golgi, where they 
can pick up escapes clients. The chaperones carry at their C-terminus a lysine aspartate glutamate 
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leucine (KDEL) or related tetrapeptide, which is recognized by KDEL receptors in the Golgi. The 
ternary client– chaperone–KDEL receptor complex is then sorted to COPI-coated vesicles that 
travel back to the ER for further client folding attempts. 
Immature proteins that don’t leave the ER lumen are retro-translocated to the cytosol. Here, 
they are de-glycosylated, ubiquitinated, and, finally, degraded by the proteasome, thanks to a 
process referred to as ER-associated degradation (ERAD). Rarely, misfolded clients may escape 
ERAD and accumulate in the ER, sometimes even forming aggregates.  
 
2.5 The Unfolded Protein Response 
 
Different conditions such as hypoxia, low or high glucose, and low PH, can induce a condition 
known as ER stress, which leads to activation of a highly conserved transcriptional program 
known as Unfolded Protein Response (UPR). (Cox et al., 1993; Mori, 2000).  The UPR can promote 
both pro-survival or pro-apoptotic outcomes, and in mammals is triggered by three ER-resident 
receptors: IRE1, PERK, and ATF6 (Figure4).  
Genes induced by the UPR include a full repertoire of ER chaperones and foldases, but also 
enzymes for membrane lipid synthesis that together sustain expansion of the ER and its folding 
capacity, whose sustain adaptive responses. In addition to these factors, the UPR can also entail 
 Figure 4: The impact of the endoplasmic reticulum protein-folding environment on cancer development.  (Wang and Kaufman, 2014) 
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cell death by apoptosis, where several pro-apoptotic members of the BCL-2 family of proteins 
are essential for the elimination of irreversibly damaged cells (Carpio et al., 2015).  
It is clear that the transition between adaptive UPR programs and the elimination of irreversibly 
damaged cells by apoptosis depend in part on the duration of ER stress stimulation; when the 
stress level exceeds the capability of the cells to restore homeostasis, and all adaptive responses 
have failed, the UPR induces apoptosis. 
Maladaptive ER stress responses can lie at the basis of a growing list of pathologies. For example, 
excessive insulin synthesis and a corresponding ‘overzealous’ UPR in pancreatic β-cells lead to 
their demise and, hence, type 2 diabetes; neurodegenerative diseases are also correlated  in an 
over activation of UPR and neurons cell death; finally, UPR is involved in cancer progression and 
chemoresistance (Wang and Kaufman, 2012) 
 
2.5.1 The IRE1a pathway 
 
IRE1 is the only identified ER stress sensor in yeast and is essential for the UPR in animals and 
plants (Wang et al., 1998). As an ER transmembrane protein, it monitors ER homeostasis through 
an ER luminal stress-
sensing domain and 
triggers the UPR 
through a 
cytoplasmic kinase 
domain and an 
RNase domain 
(Tirasophon et al., 
2000). There are at 
least two related 
homologs of yeast IRE1, referred to as IRE1α, constitutively expressed in all cells and tissues, and 
IRE1β, which expression is restricted to gut epithelial cells, that were identified in both murine 
and human genomes (Tirasophon et al., 1998; Wang et al., 1998). IRE1 appears as monomer that 
displays an individual catalytic center (Chen and Brandizzi, 2013). These monomers dimerize, 
upon induction of ER stress, facilitating trans-auto-phosphorylation and triggering an allosteric 
change, thus leading to an RNase-active complex (Korennykh et al., 2009), which promotes the 
Figure 5: The essential biology of the endoplasmic reticulum stress response for structural and 
computational biologists. (Wakabayashi and Yoshida, 2013) 
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unconventional splicing of Xbp1 mRNA, and the degradation of multiple other mRNAs through 
the so called Regulated IRE1-Dependent Decay (RIDD) (Figure 5). 
Through its kinase domain, and consequent recruitment of the TRAF2/ASK1 complex, IRE1 can 
induce the phosphorylation and activation of JNK, which is sustained by the binding  of DAB2IP 
(DAB2 Interacting Protein), and its consequent pro-apoptotic signaling (Nishitoh et al., 2002; 
Urano et al., 2000, Luo et al., 2008). Through its RNAse domain, IRE1 promotes both pro-survival 
and pro-apoptotic pathways. Studies in mammals indicate that XBP1s has a pro-survival output, 
which is often overactive in cancer, whereas RIDD has a pro-apoptotic output that dominates in 
other diseases, such as diabetes (Han et al., 2009). Under basal conditions, XBP1 mRNA is not 
spliced under low ER stress, XBP1 mRNA splicing increases progressively and decreases upon 
chronic stress (Han et al., 2009). By contrast, RIDD displays constitutive activity under basal 
conditions, called basal RIDD (Dejeans et al., 2012; Pluquet et al., 2013), increasing proportionally 
with stress intensity or duration (Maurel et al., 2014). This suggests that RIDD maintains ER 
homeostasis under low/chronic ER stress, and contributes to apoptosis under irremediable ER 
stress (Han et al., 2009).  
XBP1s is typically associated with pro-survival outcomes, it regulates a subset of UPR-induced 
genes that participate in folding, quality control, and ERAD (Arensdorf et al., 2013). Moreover, it 
is proposed that XBP1s regulates genes involved in many aspects of ER function and physiology, 
and induction of XBP1s results in an increase of ER and Golgi content (Shaffer et al., 2004). Loss 
of XBP1 in Paneth cells induces a massive disorganization of ER network and subsequent failure 
of cell development (Huh et al., 2010). XBP1s also promotes Triple Negative Breast Cancer (TNBC) 
by controlling the HIF1a pathway. In breast cancer cell lines, depletion of XBP1 inhibits tumor 
growth and tumor relapse. Genome-wide mapping revealed that XBP1 drives TNBC 
tumorigenicity by assembling a transcriptional complex with HIF1a, that regulates the expression 
of HIF1a target genes (Chen et al., 2014). 
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The PERK pathway 
 
The ER luminal portion of PERK contains a stress-sensing domain that is both structurally and 
functionally related to that of IRE1. The cytoplasmic portion of PERK also has a protein kinase 
domain that is activated when 
PERK oligomerizes in stressed 
cells (Figure 6). Once PERK is 
activated, it phosphorylates 
the α-subunit of the 
eukaryotic translation 
initiation factor-2 (eIF2α), 
resulting in globally 
attenuated translation, thus 
reducing the protein load at 
the ER (Harding et al., 1999). 
Short-lived proteins such as 
CyclinD1 decay rapidly under 
these conditions, leading to 
cell cycle arrest (Brewer and Diehl, 2000). Although cap-dependent translation is inhibited, 
translation of certain transcripts is increased. In particular, transcription factor as ATF4 is 
selectively induced in response to eIF2α phosphorylation. 
ATF4 upregulates the expression of various pro-survival genes including many ER chaperones and 
antioxidative factors. 
Interestingly, ATF4 target genes also include well-known pro-apoptotic factors such as CHOP/ 
GADD153 and Noxa. In particular CHOP is a transcription factor that inhibits cell proliferation and 
induces apoptosis. CHOP can act as both a transcriptional repressor and activator. For example, 
it suppresses the expression of the multi-domain anti-apoptotic protein Bcl-2, but induces 
expression of GADD34, a subunit of a phosphatase complex that dephosphorylates eIF2α. It has 
been proposed that eIF2α de-phosphorylation mediated by CHOP-induced GADD34 defines a 
negative feedback loop that may enhance ER stress-induced apoptosis (Oyadomari and Mori, 
2004). 
Figure 6: The essential biology of the endoplasmic reticulum stress response for structural 
and computational biologists. (Wakabayashi and Yoshida, 2013) 
15 
 
CHOP has been shown to be involved in ER stress-induced apoptosis both in vitro and in vivo. 
CHOP-deficient MEFs (mouse embryonic fibroblasts) are partially protected against ER stress-
induced apoptosis, and kidneys of CHOP−/− mice showed less apoptosis after treatment with the 
ER stressor tunicamycin, an inhibitor of glycosylation (Zinszner et al., 1998). 
CHOP upregulates expression of the BH3-only pro-apoptotic protein Bim, and the pro-apoptotic 
death receptor DR5, thus sensitizing cells to apoptosis during ER stress (Yamaguchi and Wang, 
2004). Another CHOP target gene that may be involved in cell death is ERO1α, which normally 
contributes to the oxidative environment in the ER, which is crucial for disulphide bond formation 
(Marciniak et al., 2004). 
Thus, transcriptional changes induced by PERK activation can impact the choice between cell 
survival and apoptosis. It has been proposed that the duration of PERK signaling relative to that 
of XBP1 activation may influence this critical decision-making process: in response to prolonged 
ER stress, XBP1 splicing is attenuated, while PERK activity is maintained. This may shift the cell 
towards a more destructive fate given the above mentioned connections between PERK signaling 
and the activation of pro-apoptotic proteins (Liu and Ye, 2011).  
Notably, in addition to eIF2a, PERK activation induces the phosphorylation of the transcription 
factor NRF2 (Cullinan and Diehl, 2004). Normally, NRF2 is kept in check by interaction with the 
protein KEAP1. Upon phosphorylation by PERK, NRF2 is liberated from KEAP1 and translocates 
to the nucleus where it activates genes encoding antioxidant proteins (Cullinan and Diehl, 2004). 
This activation of NRF2 by PERK is an important adaptive mechanism, as NRF2-deficient cells 
displays enhanced apoptosis during ER stress (Cullinan and Diehl, 2004).  
PERK’s activity is strictly linked with cancer progression; for example, various studies have shown 
that Nrf2 may protect cancer cells from chemotherapeutic agents, and facilitate cancer 
progression (Jaramillo and Zhang, 2013). Nrf2 is aberrantly accumulated in many types of cancer, 
and its expression is associated with a poor prognosis in patients. In addition, Nrf2 expression is 
induced during the course of drug resistance. Collectively, these studies suggest that Nrf2 
contributes to both intrinsic and acquired chemoresistance (Jaramillo and Zhang, 2013). 
Recently, Walerych et al provided evidence that confirmed the pro-tumoral activity of NRF2; they 
found that p53 missense mutants can cooperate with Nrf2 (NFE2L2) to activate proteasome gene 
transcription, resulting in resistance to the proteasome inhibitor carfilzomib (Walerych et al., 
2016).  
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In line with the important role of PERK/NRF2 complex to regulate anti-oxidative responses, loss 
of PERK in cancer cell lines significantly impaired cellular ROS buffering mechanisms, resulting in 
oxidative DNA damage and subsequent engagement of the DDR checkpoint (Bobrovnikova-
Marjon et al., 2010).  
Interestingly, PERK may also be directly involved in activation of ATF6. In fact, loss of PERK in liver 
cell lines impaired ER stress responses, and in particular ATF6 transcriptional activity. Authors 
proposed that ATF4 activity facilitates trafficking of ATF6 from the ER to the Golgi, thus enhancing 
ATF6 processing and ATF6-dependent transcription of gene involved in regulation of ERAD, 
chaperones, and vesicular trafficking (Teske et al., 2011). 
 
 
The ATF6 pathway 
 
The third player involved in the response to ER stress is ATF6. Mammalian ATF6 is an ER 
transmembrane protein of 90 kDa that under different stress conditions is transported to the 
Golgi compartment, where it is cleaved by 
S1P/S2P proteases releasing its cytoplasmic 
doman, in a similar way to SREBP proteins 
(Figure 7) (Haze et al., 1999). The ER to Golgi 
transport occurs with the help of PDIA5 
(protein disulfide isomerase A5) and COPII 
vesicles components sec24/sec23, that are 
required for full ATF6 activation (Higa et al., 
2014; Nadanaka et al., 2006).  
The cleaved form of ATF6 (ATF6-f) promotes 
transcription of UPR target genes through 
binding of three different consensus 
sequences: CCAAT-N-CCACG (ERSE-I), 
ATTGG-N-CCACG (ERSE-II) and 
TGACGTGG/A (UPRE) (Kokame et al., 2001; 
Wang et al., 2000). Interestingly, ATF6-f is 
present in a functional complex with transcription factor NF-Y, and the high-affinity for NF-Y 
Figure 7: The essential biology of the endoplasmic reticulum stress 
response for structural and computational biologists. (Wakabayashi and 
Yoshida, 2013) 
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binding site confers selectivity among different ERSEs (Yoshida et al., 2000). Similarly, interaction 
with YY1 enhances ATF6-f transcriptional activity (Li et al. 2000). 
The main transcriptional targets of ATF6-f are correlated with ER adaptive response, including 
chaperones and ERAD components, but it is also demonstrated that ATF6-f regulates cholesterol 
and lipid biosynthesis (Adachi et al., 2008; Maiuolo et al., 2011; MARUYAMA et al., 2013; 
Yamamoto et al., 2010; Zeng et al., 2004).  
As a matter of fact, ATF6 deletion compromises the functionality of the secretory pathway during 
ER stress and impairs adaptation to chronic ER stress (Wu et al. 2007). Interestingly, it has been 
reported that ATF6 antagonizes SREBP-2 to regulate the homeostasis of lipids and glucose. In 
particular, ATF6-f can bind and inhibit nuclear SREBP-2, affecting its lipogenic effect in liver cells 
(Zeng et al., 2004).  
Hereditary mutations in the ATF6 gene are associated to an autosomal recessive disease known 
as Achromatopsia (Kohl et al., 2015), characterized by cone photoreceptor dysfunction. The 
authors classified ATF6 mutations in three classes: class 1 ATF6 mutants present impaired ER-to-
Golgi trafficking, diminished intramembrane proteolysis, and reduced transcriptional activity; 
class 2 ATF6 mutants are active even in the absence of ER stress; class 3 mutants present absent 
or defective β-ZIP domains causing complete loss of transcriptional activity.  
Using primary fibroblasts from patients with class 1 or class 3 ATF6 mutations, the authors 
observed increased cell death in response to ER stress, elegantly proving that ATF6 function 
correlates with cell survival (Chiang et al., 2016). Thus, exposure to ER-stress during retinal 
development may contribute to cone dysfunction in children with ATF6 mutations (Chiang et al., 
2016). ATF6 also controls transcription of XBP1, and silencing of ATF6 reduced XBP1s levels 
(Yoshida et al., 2001). Therefore, these two pathways are interconnected.  
Since ATF6 and XBP1s can bind the same DNA-consensus sequences, it is difficult to dissociate 
these two pathways, as ATF6 and XBP1s share a number of common target genes. In order to 
define specific targets of XBP1s and ATF6, Yamamoto et al. created ATF6-KO mice and 
demonstrated that both proteins cooperate for the transcription of target genes involved in the 
regulation of protein quality control, but only ATF6 is implicated in transcription of chaperones 
(Yamamoto et al. 2007). 
The pro-survival and pro-adaptive function of ATF6 may also be involved in neurodegenerative 
diseases. For instance, Parkinson disease is linked to aberrant accumulation of α-synuclein; in a 
recent work, authors found that accumulation of α-synuclein inhibits ATF6 function. α-synuclein 
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directly interacts with ATF6 and indirectly prevents its incorporation in COPII vesicles for Golgi 
transport. Impaired ATF6 activation results in defective ERAD and apoptosis of neuronal cells 
(Credle et al., 2015). 
In addition to pro-survival functions, ATF6 can also have pro-apoptotic functions, as ATF6-f 
transactivates CHOP (Gotoh et al. 2002). Indeed, it was demonstrated that ATF6 and CHOP are 
the main mediators of apoptosis in macrophages treated with Nitric Oxide (NO) (Gotoh et al. 
2002). 
 
2.6 Endoplasmic Reticulum Stress and Malignancy 
 
ER stress is a hallmark of many different pathological states, including metabolic syndrome, 
neurodegenerative diseases, and cancer. As shown in Figure 8, conditions that induce ER stress 
as dysregulated proliferation, oxidative stress, nutrient and lipid deprivation, hypoxia, and acidic 
extracellular pH are 
characteristic for 
neoplasms. Despite these 
adverse conditions 
cancer cells are able to 
adapt and to survive by 
activating different 
responses: autophagy,  
inflammation and UPR. In 
particular, the 
endoplasmic reticulum 
(ER) regulates this 
adaptive capacity by 
coordinating a large 
number of fundamental 
cellular processes, 
including transmembrane and secretory protein folding, lipid biosynthesis, drug detoxification, 
and calcium storage and signaling.  
 
Figure 8: Endoplasmic Reticulum Stress and the Hallmarks of Cancer (Urra et al., 2016) 
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Understanding the mechanisms of the multiple cellular pathways and outcomes triggered by ER 
stress will lead to the development of novel therapeutics to prevent or treat disease. 
Healthy tissues are able to sense the accumulation of misfolded proteins beyond a tolerable 
threshold and, depending on the stress burden, to improve ER protein-folding capacity or to 
induce apoptosis. In contrast, tumor tissues change these responses and take advantages from 
them to promote cancer progression. Indeed, ER stress responses have been documented to be 
activated in most major types of human cancer, including breast, pancreatic, lung, skin, prostate, 
brain, and even liquid malignancies (Wang and Kaufman, 2014). Furthermore, ER stress 
frequently correlates with advanced-stage disease and chemoresistance. 
Cancer cells have developed mechanisms to tolerate persistent ER stress possibly by taking 
advantage of the UPR response (Urra et al., 2016). UPR activation in transformed cells is 
regulated by both intrinsic and extrinsic factors.  
 
2.6.1 Cell-intrinsic mechanisms  
 
Cancer initiation and development correlate with an increase in protein synthesis and 
augmented request of membrane and lipids. As matter of fact, loss of the tumor suppressors 
p53, PTEN, TSC1, or TSC2 dramatically enhances protein synthesis rates, leading to ER stress (Fu 
et al., 2008; Kang et al., 2011; Namba et al., 2015). Similarly, enhanced protein synthesis and 
concomitant ER stress are also observed upon overexpression of oncogenic HRAS (G12E), BRAF 
(V600E), c-Myc, or Src (Hazari et al., 2016). Interestingly, both UPR signaling and leukemia 
development induced by conditional PTEN deletion or c-Myc overexpression were reduced or 
abrogated upon deletion of the key translation rate regulator ribosomal protein RPL24, 
implicating that protein synthesis rate is a key driver of ER stress and tumorigenicity in vivo 
(Hazari et al., 2016). It has been proposed that initially transformed cells may undergo ER stress 
in response to the higher replicative and metabolic demands but can adapt by enhancing steady-
state ER protein-folding capacity (Huber et al., 2013). 
In addition, de novo genetic mutations giving rise to aberrant proteins, and other cell-intrinsic 
and cell-extrinsic stresses, likely contribute to the chronic UPR observed in most major cancer 
types (Wang and Kaufman, 2014).  
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Cell-extrinsic mechanisms  
 
Many extrinsic mechanisms present in tumor microenvironment are involved in the induction of 
ER stress. Normal and healthy cells use oxidative phosphorylation or anaerobic glycolysis to 
generate ATP, in contrast, throught the well know Warburg effect, cancer cells prefer aerobic 
glycolysis. According to this, cancer cells consume glucose and release large quantities of lactic 
acid, which lowers the extracellular pH. In addition to acidosis, solid tumors experience limited 
nutrient availability and hypoxia, all known activators of ER stress.  
Low oxygen increases cytosolic ROS production. ROS, are required for both stabilizing HIF1a, the 
key hypoxia response transcription factor, involved both in ER stress and cancer progression and 
in generating peroxidized lipids, which could form destructive covalent adducts with various ER 
chaperones. Deprivation of glucose and glutamine limits metabolic intermediates required for 
the hexosamine biosynthetic pathway (HBP), crucial for N-linked protein glycosylation and 
required for successful ER protein folding. Prolin starvation can also induce ER stress, potentially 
by inducing excessive ROS accumulation (Cubillos-Ruiz et al., 2017).  
 
ER stress and cancer: Friend or Foe? 
 
It was proposed that cancer cells by tacking advtanges from UPR pro-survival activities are able 
to promote cancer development and homeostasis mantainance (Figure 9). These include 
sustaining viability under hypoxia and nutrient deprivation, enhancing metastatic spread by 
supporting EMT, tumor cell dormancy, and 
stimulating angiogenesis. As ER stress is a 
common feature of aggressive cancers, 
understanding how the UPR modulates this 
disease is critical for identifying promising 
new clinical strategies. 
ER stress dictates cell fate depending on 
context and signal strength. Prolonged and 
severe pharmacological ER stress can trigger 
caspase-mediated cell death through several 
IRE1a- and PERK-dependent mechanisms. Despite pro-apoptotic mechanisms, mammalian cells 
Figure 9: Endoplasmic Reticulum Stress and the Hallmarks of Cancer (Urra 
et al., 2016) 
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have evolved multiple adaptive mechanisms to ER stress-mediated cell death. For example, MEFs 
exposed to persistent low-grade pharmacological ER stress resist by sustaining pro-survival 
Hspa5 (GRP78) mRNA stability and reducing pro-apoptotic Ddit3 (CHOP) mRNA stability 
(Rutkowski et al., 2006). Furthermore, STAT3 and NF-kB, which can be activated both by IRE1a 
and PERK, transcriptionally upregulate multiple anti-apoptotic proteins (Tabas and Ron, 2011). 
Additionally, ATF6-dependent p58(IPK) limits apoptosis during oncogenic transformation by 
repressing PERK activity (Huber et al., 2013).  
In summary, it appears that if cells successfully limit pro-apoptotic UPR outputs, ER stress confers 
survival advantages during tumor progression. Hypoxia and nutrient deprivation induce XBP1 
splicing, which sustains cell growth and viability in human breast cancer cell lines in vitro and in 
vivo (Chen et al., 2014). PERK-mediated NRF2 stabilization, glutathione synthesis, and HO-1 
upregulation collectively reduce cytotoxic ROS levels to facilitate cancer cell growth (Cullinan et 
al., 2003). 
Indeed, invasive cancer cells require PERK-mediated autophagy to resist anoikis, a form of cell 
death triggered by extracellular matrix (ECM) detachment. (Avivar-Valderas et al., 2011). Indeed, 
human breast ductal carcinomas also exhibit higher PERK phosphorylation than normal breast 
tissue, attesting to the physiological relevance of this mechanism (Avivar-Valderas et al., 2011).  
The UPR also has a role in sustaining metastasis. In this context, PERK has been reported to have 
a crucial role in dampening E-cadherin and overexpressing Twist, thereby enhancing migration 
and tumorsphere formation (Feng et al., 2014). Moreover, ATF4 target genes also correlate with 
an EMT gene signature in breast, colon, gastric, lung, and mixed origin metastatic cancers. 
Notably, pre-treating cells with a PERK inhibitor or silencing ATF4 dramatically reduce in vivo lung 
metastasis (Linares et al., 2017). 
Notably, the UPR might be involved in dormancy of metastatic cells. Dormant cells are often 
quiescent and exhibit reduced metabolic rates, which can insulate them from many anticancer 
drugs that rely on active proliferation. Disseminated tumor cells in the bone marrow of breast 
cancer patients exhibit high expression of multiple ER chaperones, including BiP, which protects 
these cells from hypoxia and glucose deprivation (Yang et al., 2016). Dormancy-associated 
chemoresistance require both BiP and PERK, as silencing BiP or overexpressing a dominant-
negative PERK variant sensitize cancer cells to doxorubicin and etoposide-mediated apoptosis 
(Yang et al., 2016). In addition, dormant cells showed constitutive ATF6-f nuclear translocation, 
which was partially dependent on p38 signaling (Teodoro et al., 2012). Despite ATF6 was not 
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required for tumor cell growth in vitro, silencing ATF6 sensitized cells to rapamycin treatment 
and reduced tumor nodule size in vivo (Schewe and Aguirre-Ghiso, 2008).  
A genetic polymorphism that increases mRNA expression of ATF6 and its downstream genes has 
been associated with susceptibility to hepatocellular carcinoma (Wu et al., 2014). More 
importantly, GRP78/BiP, a direct transcriptional target of ATF6α, has been reported to serve as a 
malignancy marker for cells. BiP expression not only correlates with cancer cell proliferation and 
histological grade but also correlates with response to therapies and prognosis (Yao et al., 2015).  
Indeed,  XBP1s also correlates with malignancy, and silencing of XBP1 strongly inhibited 
mammosphere growth in TNBC cell lines and primary patient samples (Chen et al., 2014). 
Inducible silencing of XBP1 in established TNBC xenografts significantly reduced primary tumor 
growth, angiogenesis, secondary metastases, and tumor recurrence after chemotherapy, 
without enhancing tumor cell death (Chen et al., 2014). Taken together these data suggests that 
all three UPR branches may promote metastasis by sustaining cell invasion, dormancy, and 
seeding. 
The UPR may also regulate angiogenesis. Solid tumors must produce new vessels to supply 
oxygen and nutrients for growth and to remove toxic products.. In this particular context, XBP1, 
ATF4, and ATF6a can transcriptionally upregulate VEGFa under hypoxia or glucose deprivation by 
directly or indirectly binding the VEGF promoter (Karali et al., 2014). Neovascularization is also 
mediated by a number of pro-angiogenic cytokines, including fibroblast growth factor 2 (FGF2), 
interleukin-6 (IL-6), IL-8, and angiogenin, whose expression appears to be sustained by IRE1a 
activity (Chen et al., 2014).  
Finally, the UPR might modulate interaction of cancer cells with their microenvironment. The 
tumor microenvironment is characterized by the presence and the cooperation of different 
cellular type: stromal cells, fibroblasts, cancer cells and immune cells (Quail and Joyce, 2013). In 
the last years, the interaction between the immune system and cancer progression obtained 
strong interest. Interestingly, upon ER stress cancer cells are able to transmit to immune system 
cells a signal of proliferation, using a process termed as ‘‘transmissible ER stress’’, which affects 
the antigen-presenting capacity of bone-marrow-derived dendritic cells (DCs) while provoking 
overexpression of immunosuppressive molecules (Mahadevan et al., 2012). These studies 
suggested that ER-stressed cancer cells secrete factors that modulate innate immune cell 
functions, but whether this process contributed to tolerance and/or immunosuppression in 
cancer hosts is still unknown (Rodvold et al., 2017). Importantly, subsequent studies 
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demonstrated that administration of the ER stressor thapsigargin to tumor-bearing mice 
accelerates cancer progression and stimulates the accumulation and immunosuppressive 
capability of myeloid-derived suppressor cells (MDSCs), a process that could be alleviated upon 
treatment of cancer hosts with chemical chaperones that reduce ER stress (Lee et al., 2014). 
Chronic inflammation is also associated with UPR, and can contribute to all stages of cancer 
development and progression. As shown in several pathological conditions, ER stress and UPR 
activation are involved in the signal transduction and transcriptional regulation of inflammatory 
mediators (Lerner et al., 2012; Oslowski et al., 2012).  
 
2.7 Targeting UPR in cancer 
 
Giving the pre-existing ER stress induced by intrinsic and extrinsic factors in cancer cells, 
compounds that increase ER stress levels should induce apoptosis.  
One strategy is to increase the amount of unfolded proteins in the ER lumen by inhibiting 
proteasome-dependent degradation.  
To this aim Bortezomib, the first proteasome inhibitor for cancer therapy approved by the US 
Food and Drug Administration (FDA), 
obtained success as an ER stress 
inducer and in treating multiple 
myeloma. More importantly, the 
sensitivity to proteasome inhibitors 
correlates with low XBP1 (or XBP1s) or 
ATF6α levels suggesting their 
involvement in tumor progression.  
Some new emerging drugs are 
designed to target specific UPR 
pathways to inhibit UPR activation, 
thereby augmenting ER stress in 
cancer cells (Figure 10). 
 
 
 
Figure 10: Protein misfolding in The Endoplasmic Reticulum as a conduit to human 
disease. (Wang and Kaufman, 2016) 
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2.7.1 IRE1a endo-ribonuclease activity inhibitors 
 
Sustained IRE1a-XBP1 signaling promotes cancer-cell-intrinsic growth, metastasis, and 
chemoresistance, but its surprising role as a key modulator of myeloid cell function in tumors 
emerges as an attractive target for cancer immunotherapy. Whereas direct pharmacological 
inhibition of nuclear XBP1 is difficult due to major technical limitations, targeting its upstream 
activator, IRE1a, represents a viable strategy.  
Indeed, the dual enzyme IRE1a is amenable to small-molecule targeting, and two classes of direct 
inhibitors have been identified. The first group of compounds directly targets the IRE1a 
endoribonuclease domain, and some examples of this class include toyocamycin (Ri et al., 2012), 
STF-083010 (Papandreou et al., 2011), 4m8C (Cross et al., 2012), MKC-3946 (Mimura et al., 2012), 
and B-I09 (Tang et al., 2014). Notably, these direct IRE1a endonuclease inhibitors are capable of 
blocking Xbp1 splicing without affecting IRE1a phosphorylation or the PERK and ATF6a arms of 
the UPR. STF-083010, MKC-3946, and toyocamycin demonstrated therapeutic efficacy in multiple 
myeloma xenograft models, and B-I09 has been shown to control the aggressiveness of chronic 
lymphocytic leukemia cells in vivo (Tang et al., 2014). The second group of inhibitors targets the 
IRE1a kinase domain in order to allosterically disrupt its endoribonuclease function. A recent 
compound in this category is KIRA6 (Ghosh et al., 2014), which reduced plasma glucose levels 
and improved glucose tolerance in Ins2+/Akita mice that exhibit chronic ER stress in pancreatic 
b cells (Ghosh et al., 2014). Moreover, intravitreal KIRA6 injection in the P23H transgenic rat 
model of retinitis pigmentosa preserves photoreceptor viability and function (Ghosh et al., 2014). 
Nevertheless, it has not been determined whether treatment with IRE1a inhibitors fully 
recapitulates the biological effects of IRE1a genetic ablation. Developing novel IRE1a inhibitors 
with potent in vivo efficacy in the tumor microenvironment could therefore be useful to directly 
restrain cancer cell survival, metastasis, and chemoresistance, while eliciting protective anti-
tumor immune responses via myeloid cell reprogramming.  
 
PERK inhibitors 
 
GSK2606414 was the first reported PERK inhibitor (Axten et al., 2012) and was found to be 
neuroprotective in mouse models of prion disease (Moreno et al., 2013). Another ATP- 
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competitive inhibitor of PERK enzymatic activity, GSK2656157, was shown to impede ER-stress-
induced PERK autophosphorylation, eIF2a phosphorylation, and subsequent overexpression of 
ATF4 and CHOP in multiple cell lines (Atkins et al., 2013). Oral administration of GSK2656157 to 
mice impaired PERK auto-phosphorylation in the pancreas and compromised xenograft tumor 
growth in immunodeficient hosts (Atkins et al., 2013). However, further studies indicate that 
inhibition of PERK activity by GSK2656157 does not always correlate with reduced eIF2a 
phosphorylation and that this inhibitor fails to recreate the biological effects of PERK genetic 
inactivation (Krishnamoorthy et al., 2014). The integrated stress response inhibitor (ISRIB) is a 
symmetric bis glycolamide that renders cells resistant to eIF2a phosphorylation, thereby blocking 
the activation of ATF4 and the accumulation of CHOP during conditions of ER stress (Sidrauski et 
al., 2015). Whether GSK2656157 or ISRIB could modulate the function or survival of MDSCs in 
the tumor microenvironment by impeding PERK/eIF2a-mediated CHOP activation is yet to be 
tested. Given the importance of PERK and IRE1a-XBP1 signaling in organ homeostasis of highly 
secretory tissues, careful optimization of these inhibitory compounds for in vivo use is essential 
to minimize potential side effects and toxicity in treated hosts.  
 
ATF6 inhibitors 
 
Nelfinavir is the first identified ATF6 inhibitor. It was created as inhibitor of viral proteases but 
Nelfinavir and its analogs are also able to inhibit the proteases S1P and S2P, that cleave ATF6 and 
SREBP1 into the Golgi compartment (Guan et al., 2011; Koltai, 2015). Giving the non-specific 
action of Nelfinavir, another class of ATF6 inhibitors has been recently discovered by Walter and 
its group. Ceapins, a new class of pyrazoleamides, have been recently demonstrated to 
specifically inhibit the ATF6a branch of the UPR by blocking ATF6a processing and nuclear 
translocation in cells undergoing ER stress (Gallagher and Walter, 2016). Ceapins are rather toxic, 
therefore further optimization of Ceapins for in vivo use will hence be critical for determining the 
anti-tumor activity of these compounds alone or in combination with other agents that ablate 
PERK and/or IRE1a signaling in the tumor microenvironment. 
 
Another important finding, which shows that targeting the UPR may be a promising approach for 
cancer therapy, is that GRP78/BiP is expressed on the surface on cancer cells but not normal cells. 
Overexpression of BIP in cancer cells correlates with chemotherapy resistance (Yao et al., 2015). 
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In addition, expression of BIP seems to be increased in the tumor vasculature, suggesting that 
targeting BIP will have an impact on both cancer cells and the tumor microenvironment (Roller 
et al., 2013). 
 
However, as UPR activation has both pro-survival and anti-survival effects on cells, caution is 
necessary in the design of therapies that target UPR components and in the interpretation of the 
results. Specific gene targeting experiments are required to dissect the requirement for different 
UPR transduction pathways in the tumor and the microenvironment. Indeed, ER stress and UPR 
activation may also alter the cancer cell response to adjuvant therapies, offering an opportunity 
for drug combination treatments. One therapeutic rationale is to induce ER stress and UPR 
activation to activate death pathways in cancer cells. Alternatively, preventing UPR activation 
could sensitize cancer cells to other therapies, as the UPR promotes adaptation and drug 
resistance. Anti-angiogenesis therapies are not adequate alone, but they may show synergy in 
combination with anti- UPR agents. 
In summary, combination therapies using drugs targeting the UPR together with drugs targeting 
specific oncogene, for example mutp53, may become promising anticancer approaches. 
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3. Aim of the thesis 
TP53 is one of the most frequently mutated genes in human cancer. Wild-type p53 is involved in 
the activation of apoptotic outcomes in a variety of different stresses conditions, but its role in 
the response to ER stress in not fully understood. Cancer associated mutant p53 proteins acquire 
powerful oncogenic activities (gain of function), and almost nothing is known about mutant p53 
and ER stress. What appears clearly from the literature is that mutant p53 can sustain 
proteasome activity (Walerych et al., 2016), N-glycosylation of proteins (Vogiatzi et al., 2016), 
and HSF1 transcriptional activity (Li et al., 2014). Although these functions are indirectly 
connected to ER stress, whether mutant p53 can directly modulate the Unfolded Protein 
Response (UPR) pathway is not clear. 
ER stress is a common feature of different types of blood and solid cancers. Adaptation to ER 
stress is achieved by the activation of the UPR. Some targets and mediators of UPR favor 
resistance of cancer cells to ER stress. Moreover, cancer cells are able to transmit this resistance 
to the other cells present in tumor microenvironment (immunity cells, stromal cells and 
fibroblasts) favoring tumor growth and chemoresistance. For all these reasons, ER stress and UPR 
are gaining increasing attention as new targets for cancer treatment. 
Based on these premises, we hypothesize that mutant p53 can help maintain ER stress under the 
threshold levels that induce apoptosis, thus sustaining cancer cell survival. We also hypothesize 
that mutp53 does so by modulating the signaling responses that are triggered by ER stress. 
Aim of this Thesis is to define the role of mutant p53 in the response to ER stress in model cancer 
cell lines. It also aims to study the molecular mechanisms by which mutant p53 might influence 
the UPR signaling network. Finally, this work aims to explore the potential benefits of inhibiting 
selected components of the UPR as a novel approach to reinforce the efficacy of mutp53-
targeting drugs. 
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4. Results 
 
Walerych and colleagues have recently compared transcriptome and proteome of five triple-
negative breast cancer cell lines bearing different p53 mutations, and found that mutant p53 
(mutp53) sustains expression of genes encoding proteasome subunits. Increase in these genes 
correlates with cancer cells invasion and chemoresistance and they proposed that these 
phenotypes were dependent on a new gain-of-function of mutant p53 (Walerych et al., 2016). 
Interestingly, in addition to the proteasome, their data suggest that mutant p53 regulates other 
homeostatic processes and in particular the Unfolded Protein Response (Figure 1). Starting from 
this observation and from the evidences that UPR’s pro-survival effects are improved in cancer 
cells to increase resistance to proteostasis insult, I hypothesized that mutant p53 is controlling 
Unfolded Protein Response to sustain survival and to maintain homeostasis. 
 
 Mutant p53 protects cancer cells from ER stress-induced apoptosis 
 
To deepen our understanding on the role of mutant p53 in UPR, we started evaluating survival 
of cancer cell lines exposed to ER stress. To mimic severe ER stress conditions, we treated cells 
with two widely used drugs: Thapsigargin (Tg) and Tunicamycin (Tm). Tg is a specific inhibitor of 
the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). Treatment with Tg results in a 
decrease in ER calcium levels, so that calcium-dependent ER chaperones, such as calnexin, lose 
their activity, leading to the accumulation of unfolded proteins. Tm is an inhibitor of UDP-N-
acetylglucosamine-dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT); it 
blocks the initial step of glycoprotein biosynthesis in the ER, so Tm treatment causes 
accumulation of unfolded glycoproteins in the ER, leading to ER stress (Kim et al., 2009).  
To measure cancer cells viability, we used ATP-lite viability assay, which, by monitoring ATP, can 
assess the proliferative effects of a wide range of drugs, biological response modifiers, and 
biological compounds. As model, we used MDA-MB-231, a metastatic triple negative breast 
cancer cell line with mutant p53 (R280K), and measured survival upon depletion of mutp53 and 
treatment with Tg (1uM) and Tm (5ug/ml) for 48 hours. As shown in Figure 2A, depletion of 
mutant p53 rendered MB231 cells more sensitive to Tg and Tm treatment. Higher cleaved-PARP 
levels in mutp53-depleted cells indicated that this reduced viability is due to apoptosis (Figure 
2B).  
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Similar results were obtained with PANC1, a pancreatic cancer cell line with mutp53 (R175H)  and 
with SUM159, a breast cancer cell line with mutp53 (R158InF), (Fig 2C, D); therefore, this 
phenotype is not a peculiarity of MB231 cells. 
Together, these preliminary observations suggest that mutp53 confers a certain degree of 
resistance to ER stress.  
To test whether this activity may be considered as a proper GOF of mutp53, we stably 
overexpressed two different p53 mutants, R280K and R175H, in the triple negative breast cancer 
cell line HBL-100, bearing wild-type p53. This model allows us to assess the dominant effects of 
mutant p53. We performed ATP-lite assays after treating cells with Tg and Tm for 48 hours;   HBL-
100 cells overexpressing mutant p53 showed higher resistance to treatments (Figure 2E), 
suggesting that mutp53 is sufficient to promote this phenotype.  
To further confirm these observations, we compared mouse embryonic fibroblasts (MEFs) 
derived from p53 -/- and mutp53 R172H/- mice (Girardini et al., 2011). By FACS analysis we 
observed that upon 24 hours of treatment with Tg and Tm, MEFs KI for mutant p53 showed 
significantly fewer apoptotic cells with respect to p53 KO MEFs (Figure 2F). 
Together, these data support the hypothesis that mutant p53 is protecting cancer cells from ER-
stress induced apoptosis. 
 
 
Mutant p53 depletion induces different UPR activation patterns. 
 
To better understand which pathway is involved in the phenotypes observed, we started 
inhibiting, in mutant p53 bearing cells, the main mediators of UPR, IRE, PERK and ATF6, by using 
GSK-2606414 as PERK inhibitor (PERKi), STF-083010 as IRE1 inhibitor (IREi), and Ceapin_A7 as 
ATF6 inhibitor (ATF6i) (Gallagher et al., 2016; Hetz et al., 2013; Vincenz et al., 2013). Notably, in 
basal conditions (i.e., without ER stress-inducing drugs) only ATF6 inhibition had a phenotype, 
clearly reducing cell viability (Figure 3A) - suggesting that ATF6 may have a role in mutant p53 
bearing cancer cells. 
Efficiency of inhibitors was confirmed by performing three independent experiments in MDA-
MB-231. Western blot experiments were performed to measure PERK phosphorylation and ATF6 
cleavage, while XBP1s mRNA levels were measured as a readout of IRE1 alpha activation (Figure 
3B). 
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In order to understand whether mutant p53 is acting on IRE1, PERK and ATF6 expression, we 
analyzed mRNA and protein levels of IRE, PERK and ATF6 upon mutp53 depletion. Notably, MDA-
MB-231 depleted for mutp53, showed increase in mRNA and protein levels of IRE1 and PERK, 
and, interestingly, showed a reduction in cleaved ATF6 protein (Figure 3C). 
This suggests that mutant p53, in unstressed conditions, is maintaining low levels of IRE1 and 
PERK and is sustaining ATF6 cleavage. 
Since, IRE1a and PERK are mainly mediators of ER stress-induced apoptosis (Tabas and Ron, 
2011), while ATF6 is largely involved in the transcription of chaperones, ERAD components, and 
protein quality control enzymes, we hypothesized that mutant p53 is inhibiting IRE1 and PERK to 
block apoptotic signals, and it is sustaining ATF6 activity to maintain ER homeostasis. 
 
Mutant p53 inhibits IRE1a and PERK functions but promotes ATF6 transcriptional activity. 
 
In order to evaluate, whether upregulation of IRE1 and PERK activities impinge on their activation 
upon silencing of mutant p53, we measured both kinase and RNase activities of IRE1 by 
quantifying XBP1 mRNA cytoplasmic splicing and JNK phosphorylation. We performed RT-qPCR 
for XBP1s and western blot experiments for pan and phospho-JNK proteins. As shown in figure 
4A, MDA-MB-231 and SUM159 depleted for mutant p53 showed increase in XBP1s expression 
and increase in JNK phosphorylation, confirming that IRE1 is more active in mutp53-depleted 
cells.  
As readout of PERK activation, we measured CHOP mRNA levels. As expected, MDA-MB-231 
depleted for mutant p53 showed increased CHOP mRNA levels (Figure 4B), indicating enhanced 
PERK activity.  
We observed that mutant p53 depletion reduced the cleaved form of ATF6 (Figure 3A). The ATF6f 
fragment is a DNA-binding transcription factor, and promotes transcription of UPR target genes 
(Kokame et al., 2001; Wang et al., 2000); therefore, as readout of ATF6f activity we used a 
luciferase (LUC) reporter construct harboring five repetitions of the ATF6 binding sites (Shen et 
al., 2002). We transiently transfected this construct in MDA-MB-231 stably silenced for mutant 
p53 (shp53), and observed a reduction in luciferase signal upon mutp53 depletion (Figure 4C). 
Importantly, the results of loss-of-function experiments were confirmed by gain-of-function 
experiments, as stable expression of two different p53 mutants in p53-null H1299 cancer cells 
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reduced CHOP and XBP1s mRNA induction, and enhanced ATF6 transcriptional activity (Figure 
4D). 
Together, these data support the hypothesis that mutant p53 is dampening IRE1 and PERK 
activation, while sustaining ATF6 processing and transcriptional activity. 
 
 
Both JNK and CHOP are required for ER stress-induced apoptosis in mutp53-depleted cancer cells. 
 
As already mentioned, CHOP and JNK are, respectively, downstream pro-apoptotic effectors of 
PERK and IRE1a. We therefore assessed their role in ER stress-induced apoptosis in the presence 
or absence of mutant p53. To this aim, we performed ATP-lite assays upon siRNA depletion of 
JNK and/or CHOP. Interestingly, knockdown of either JNK or CHOP was sufficient to reduce cell 
death, both in untreated conditions than upon Tg or Tm treatment (Figure 5A); this indicates that 
JNK and CHOP are both required for ER stress-induced apoptosis in mutant p53 depleted cancer 
cells. 
Since there are many evidences that suggest a cooperation of JNK and CHOP in activation of 
common target genes, one of which is DR5 (Death Receptor 5), a cell surface receptor for tumor 
necrosis factor (TNF)-related apoptosis (Oh et al., 2012; Tiwary et al., 2010). We thus 
hypothesized that mutant p53, by coordinately dampening CHOP and JNK activation, may be 
blocking DR5 induction upon ER stress. To test this, we measured DR5 mRNA levels in cancer cell 
depleted for mutant p53. As shown in figure 5B, mutant p53 knockdown significantly increased 
Tg-induced DR5 mRNA transcription, and such increase was blocked by depletion of either JNK 
or CHOP.  
We next asked whether mutant p53 depletion enhances ER stress-induced apoptosis via CHOP 
and JNK-mediated DR5 induction. To test this, we repeated ATP-lite experiments in MDA-MB-
231 upon double knockdown of mutant p53 and/or DR5. As shown in figure 5 C, knockdown of 
DR5 significantly increased viability of mutp53-depleted cells, confirming that DR5 is a major 
effector of ER stress-induced apoptosis in MB231 cells, at least under these conditions. 
Together these data indicate that mutp53 depletion, possibly by increasing IRE1 and PERK 
signaling, sensitizes cancer cells to ER stress-induced apoptosis, and that such apoptosis is 
dependent on the cooperative activity of both JNK and CHOP converging on activation of a set of 
pro-apoptotic targets, among which is death receptor DR5. 
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Mutant p53 sustains ATF6 transcriptional activity by promoting its cleavage. 
 
It has been demonstrated that ATF6 activity ameliorates ER function and protects cells from 
chronic stress, since it regulates chaperones and protein quality control genes (Adachi et al., 
2008; Wu et al., 2007). In line with a pro-survival and pro-adaptive function, ATF6 was recently 
proposed as an important marker of pre-cancerous lesions associated with colorectal cancer 
(Hanaoka et al., 2017). We found that ATF6 transcriptional activity is reduced upon depletion of 
mutp53 in MB321 cells (Figure 4C), and is enhanced by overexpression of mutant p53 in p53-null 
cells (Figure 4D). 
Regarding ATF6 expression, RT-PCR experiments indicated that ATF6 mRNA levels are not 
significantly changed upon silencing of mutant p53, but immunoblotting revealed a reduction in 
ATF6f protein levels (Figure 3C). Therefore, it is possible that mutant p53 may sustain ATF6 
transcriptional activity by enhancing its translocation from ER to Golgi and consequently its 
proteolytic cleavage.  
To better address this point, we analyzed the kinetics of ATF6 cleavage induced by ER stress in 
MDA-MB-231, confirming that ER stress-induced ATF6 processing is significantly reduced upon 
mutant p53 knockdown (Figure 6A). Correspondingly, mutant p53 knockdown also dampened 
ATF6-dependent transcription as assessed by Luciferase experiments, both in untreated 
conditions than upon ER stress induction (Figure 6B). 
To test if mutant p53 may dominantly promote ATF6 processing, we analyzed ATF6f levels and 
transactivation in HBL-100 cells (wt p53) stably overexpressing R280K or R175H p53 mutants. 
Western blot experiments confirmed that mutant p53 increased ATF6f protein levels (Figure 6C), 
as well as transactivation of the ATF6-LUC reporter (Figure 6D).  
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ATF6 is required for cancer cell survival and invasion. 
 
Starting from the evidence that ATF6 inhibition using Ceapins_A7 reduces cell viability (Figure 
2B), and that mutant p53 overexpressing cells present higher basal ATF6 transcriptional activity 
(Figure 6D), we hypothesized that mutant p53 may sustain cancer cell survival, at least in part, 
by promoting ATF6-dependent chaperone production and ER homeostasis. 
To test this hypothesis, we further analyzed the impact of ATF6 depletion on viability of MDA-
MB-231 cells exposed to ER stress. In line with results obtained with pharmacological inhibition 
(Figure 3B), ATF6 depletion compromised basal viability of these cells, and strongly increased 
their sensitivity to ER stress (Figure 7A). This data further confirmed that in our model (mutp53 
TNBC cells) ATF6 has a significant pro-survival activity. 
In apparent contradiction with the above results, ATF6 depletion reduced CHOP mRNA induction 
by ER stress (Figure 7B), thus potentially counteracting apoptosis. This result is not surprising, as 
literature indicates CHOP as a transcriptional target of ATF6f (Yoshida et al., 2000). Nonetheless, 
ATF6 depletion also increased ER stress-induced JNK phosphorylation, similar to what happens 
upon silencing of mutp53 (Figure 7B), a result in line with reduced cell viability. 
One of the most important ATF6 target genes is the ER chaperone GRP78/BiP, a key regulator 
that maintains ER homeostasis, suppresses stress-induced apoptosis, and controls UPR signaling. 
Notably, increased expression of GRP78, together with other ATF6 targets, correlates with poor 
prognosis and cancer cells invasion and migration (Roller et al., 2013; Yao et al., 2015). 
We therefore hypothesized that mutant p53 could regulate ER homeostasis, enhance cell 
invasion, and suppress stress-induced apoptosis by sustaining ATF6-dependent expression of 
GRP78 and other chaperones. To test this hypothesis, we performed matrigel invasion assays 
with cells depleted for ATF6. We observed a substantial reduction in the number of invasive cells 
upon ATF6 silencing, supporting the evidence that ATF6 activity correlates with a more aggressive 
phenotype (Figure 7C). 
We also measured GRP78 mRNA and protein levels upon silencing of ATF6 or mutant p53. As 
expected, we observed a strong reduction in GRP78 mRNA and protein levels upon ATF6 
depletion (Figure 7D). Interestingly, GRP78 expression was reduced also after mutant p53 
depletion (Figure 7E), confirming the mutant p53-ATF6 regulatory axis. 
Together, these data suggest that ATF6-depletion reduces cell viability and cell invasion by 
affecting multiple parameters, including an increase in JNK activation and less efficient induction 
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of pro-survival effectors such as GRP78/BiP, and possibly other chaperones and ERAD 
components. They also suggest that the increased resilience to ER stress observed in cancer cells 
with mutant p53 may be due to increased ATF6 transcriptional activity. 
Starting from the evidence that ATF6 needs the binding of COPII vesicles components 
sec23/sec24 to be translocated into the Golgi apparatus (Schindler and Schekman, 2009), we 
asked whether mutant p53 may be enhancing expression of these proteins, since this could 
increase the ER-to-Golgi translocation of ATF6 in cancer cells. 
Intriguingly, we measured a reduction of sec24 mRNA and protein levels in MDA-MB231 cells 
upon mutant p53 knockdown (Figure 7F). These preliminary data suggest a possible involvement 
of mutant p53 in supporting expression of sec24, which in turn could promote ATF6 incorporation 
in COPII vesicles for Golgi translocation, cleavage, and activation. 
 
 
Targeting ATF6 and Mutant p53 as a new strategy for cancer therapy. 
 
ER stress can be theoretically exploited to kill tumor cells, given their strong dependency on ER 
functions to sustain proliferation, protein biosynthesis, and secretion of matrix remodeling 
enzymes, growth factors, and receptors. This could be achieved via two complementary 
approaches: one focalized on exacerbation of ER stress, the other on inhibition of UPR-
dependent pro-survival pathways. Both mutant p53 and ATF6 have been associated with cell 
survival and progression/aggressiveness in different tumor types (Adachi et al., 2008); we 
therefore sought to evaluate the possibility to enhance cancer cells’ sensitivity to ER stress by 
acting, alone or in combination, on mutant p53 and ATF6. 
To target ATF6 we used NELFINAVIR (NFV), an anti-viral compound used against HIV infection 
that inhibits the proteases responsible for ATF6 cleavage in the Golgi compartment (Guan et al., 
2011, 2015). Using our mutant p53 TNBC model, we examined cell viability upon treatment with 
NFV, alone or in combination with ER stressors Tg and Tm. A shown in figure 8A, NFV treatment 
strongly reduced cell survival, both under basal conditions and upon ER stress activation. To 
confirm that NFV inhibits ATF6 functions, we transfected an expression vector encoding an eGFP-
ATF6 fusion protein, that makes it easier to follow processing and subcellular localization of ATF6 
by detecting eGFP. Treatment with NFV efficiently blocked Tg-induced cleavage of ATF6 in MDA-
MB-231 cells (Figure 8B). Accordingly, NFV also inhibited ATF6 transcriptional activity (Figure 8C). 
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To target mutant p53, we used the FDA-approved histone deacetylase inhibitor SuberoylAnilide 
Hydroxamic Acid (SAHA), a drug that reduces mutant p53 protein levels and shows preferential 
cytotoxicity in mutant p53 cancer cells (Li et al., 2011). We analyzed viability of MDA-MB-231 
cells upon treatment with SAHA, alone or in combination with ER stress. As shown in Figure 9A, 
SAHA treatment reduced cell viability, both under basal conditions and upon treatment with Tg 
or Tm, confirming that mutp53 has a protective role under conditions of ER stress. We also asked 
if SAHA, reducing mutant p53 levels, might be affecting ATF6 processing and transcriptional 
functions; in line with data obtained with mutant p53 silencing, treatment of MB231 with SAHA 
significantly reduced ATF6f levels (Figure 9B), and transactivation of the ATF6-LUC reporter 
(Figure 9C). 
Nelfinavir and SAHA act on two different cellular targets; we therefore tested the hypothesis that 
their combination could provide a valid strategy to increase cancer cell sensitivity to ER stress. To 
this aim, we treated MB231 cells with SAHA and NFV, alone or in combination, in presence or in 
absence of ER stress inducers. Viability assays confirmed that combination of the two compounds 
was more efficient in reducing cancer cell viability than treatment with single drugs - in particular 
after ER stress (Figure 10A). To reinforce these observations, we used another mutant p53-
targeted drug, Cerivastatin (CER), a statin that was recently shown to inhibit mutant p53 stability 
and functions (Sorrentino et al., 2014). We then tested CER alone or in combination with NFV, 
using low concentrations to minimize toxicity and highlight potential cooperative effects. Under 
these conditions, combined treatment of MDA-MB-231 cells with NFV and CER recapitulated the 
results obtained with SAHA, additively reducing cell viability (Figure 10B). In order to evaluate 
the possible effects of these treatments on non-transformed cells, we performed the same 
experiments in MCF-10A breast epithelial cells. In contrast to what observed in MDA-MB231, 
treatment with CER (0,01uM) and/or NFV (12,5) did not reduce viability of MCF10A (Figure 
10C,D), providing an important indication that the additive effects of ATF6 and mutant p53 
inhibitors can be specific for cancer cells. 
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7. Figures 
 
 
 
 
Figure 1. Unfolded Protein Response is one of the biological processes regulated by different 
missense p53 mutants in a panel of human breast cancer cell lines. 
As described in Walerych et al., 2016, transcriptomic profiles of BT-549, HCC-1395, SUM-149PT, 
MDA-MB-468 and MDA-MB-231 cell lines before or after mutp53 depletion were analyzed to 
identify genes similarly regulated by different p53 mutants in different TNBC cell lines. Common 
mutant p53-regulated genes were analyzed for pathway association using IPA (Ingenuity 
Pathway Analysis – Qiagen). The graph summarizes the most enriched pathways. Bars: adjusted 
–log (P values) for pathway association. Lines: ratio of the number of genes found in the gene set 
to the total number of genes associated to each pathway (Walerych et al., 2016). 
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Figure 2 
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Figure 2. Mutant p53 sustains cancer cells survival upon ER stress.  
A-B) Mutant p53 silencing dampens cancer cell viability and increases apoptosis. A) MDA-MB-
231 cells were transfected with two different p53 siRNAs (sip53_A or sip53_B) or control (siC) 
siRNAs as indicated. 48 hours post transfection; cells were seeded in 96 well. After 24 hours, cells 
were treated with Thapsigargin (Tg) 1uM or Tunicamycin (Tm) 5ug/ml. After 48 hours, ATP-lite 
viability assays were performed. Graphs summarize cells viability normalized to untreated siC 
control (mean ± SD; n=3; ***P<0.001, **P<0.01). ATF6, PERK and p-IRE1 protein levels were 
analyzed by western blot as markers of Unfolded Protein Response activation. B) MDA-MB-231 
were treated as in A, and analyzed by western blot to detect cleaved PARP as a marker of 
apoptosis. p53 knock-down was confirmed by immunoblotting; HSP90 was used as loading 
control. 
C) PANC1 cells were transfected and treated as in A. Graphs summarize cells viability normalized 
to untreated siC control (mean ± SD; n=3; **P<0.01; *P<0.1).  
D) SUM159 were transfected as in A and treated with Tg or Tm for 24 hours and then processed 
for FACS analysis. Graphs summarize percentage of cells in sub-G1 phase (mean ± SD; n=3; 
**P<0.01; *P<0.1). 
E) Mutant p53 overexpression protects cells from ER stress. HBL100 cells were stably transduced 
with retroviruses encoding p53 (R280K) or p53 (R175H). ATPlite assays were performed as in 
Figure 2A (mean ± SD; n = 3; **p < 0.01).  
F) Mouse Embryonic Fibroblasts derived from mutp53 knock-in mice (m/m) or p53 KO mice (-/-), 
were treated with Tg or Tm for 24 hours and then processed for FACS analysis (mean ± SD; n=3; 
***P<0.001).  
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Figure 3 
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Figure 3. Mutant p53 depletion has a different impact on UPR receptors.  
A) Only ATF6 inhibition affects cancer cells viability. MB231 cells were treated with specific 
inhibitors: STF-083010 (IRE1i 60uM), GSK-2606414 (PERKi 10uM) or Ceapins_A7 (ATF6i 25uM). 
48 hours post treatment ATP-lite assays were performed as in Figure 2A (mean ± SD; n=3; 
**P<0.01;).  
B) Efficiency of inhibitors was verified in MDA-MB-231. Cells were treated for 48h with GSK-
2606414, STF-083010 or Ceapins_A7 at different concentrations, and then treated with Tg for 
4h. Phosphorylated PERK and ATF6 cleavage were measured by immunoblotting. Expression of 
XBP1s was measured by RT-qPCR after 8h of Tg 1uM (mean ± SD; n = 3; *p < 0.1). 
c) Mutant p53 depletion increases IRE1 and PERK mRNA and protein levels, but decreases ATF6f. 
MDA-MB-231 cells were transfected with mutp53 (sip53) or control (siC) siRNAs. 48 hours post 
transfection; cells were harvested for RNA or protein extraction. RT-qPCR data are normalized to 
H3 gene, and compared to expression levels of untreated cells transfected with siC. Immunoblots 
are normalized by Hsp90. 
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Figure 4 
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Figure 4. Mutant p53 dampens IRE1a and PERK functions and sustains ATF6 transcriptional 
activity. 
A) Mutant p53 depletion increases IRE1a activation. MDA-MB-231 were transfected with p53 
(sip53) and control (siC) siRNAs. After 48 hours, cells were treated with Tg (1uM) for the indicated 
times. Phosphorylated and total JNK were measured by immunoblotting. Expression of XBP1s 
was measured by RT-qPCR after 8hr of Tg 1uM (mean ± SD; n = 3; ***p < 0.001).  
B) Mutant p53 depletion increases PERK activation. Expression of CHOP mRNA was measured by 
RT-qPCR in MB231 cells treated exactly as in A (mean ± SD; n = 3; ***p < 0.001). 
C) Mutant p53 depletion reduces ATF6 transcriptional activity. MDA-MB-23, stably infected with 
control (empty vector) and p53 (sh-p53) retroviral constructs, were transfected with p5xATF6-
GL3 and pCMV-renilla constructs Transcriptional activity of ATF6f was measured by dual-
luciferase assay in cells treated as in A (mean ± SD; n = 3; ***p < 0.001).  
D) Mutant p53 overexpression decreases CHOP and XBP1s mRNA levels and promotes ATF6 
luciferase activity. H1299 were stably infected with retroviruses encoding p53 (R280K) or p53 
(R175H). RT-qPCR were performed as described in B and luciferase assays were performed as in 
C (mean ± SD; n = 3; ***p < 0.001). 
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Figure 5 
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Figure 5. Both JNK and CHOP are required for enhanced ER stress-induced apoptosis after 
mutant p53 depletion.  
A) JNK and CHOP are required for mutant p53 depletion-dependent ER stress induced apoptosis. 
MDA-MB-231 were transfected with JNK (siJNK), CHOP (siCHOP), p53 (sip53) or control (siC) 
siRNAs. After 48h, cells were harvested and treated as in Figure 2A. Viability was measured by 
ATPlite, and normalized to control untreated cells (mean ± SD; n = 3; **p < 0.01).  
B) DR5 is a common target of CHOP and JNK upon ER stress. MDA-MB-231 were transfected with 
JNK (siJNK), CHOP (siCHOP), DR5 (siDR5), p53 (sp53) or control (siC) siRNAs as indicated. After 
48hr, cells were treated and processed as in Figure 2A. DR5 expression levels were detected by 
RT-qPCR. Data are normalized to H3, and compared to untreated cells transfected with siC (mean 
± SD; n = 3; **p < 0.01). 
C) DR5 depletion reduces ER stress-induced apoptosis in mutp53 knockdown cells. MDA-MB-231 
were transfected with DR5 (siDR5), p53 (sip53) or control (siC) siRNAs as indicated. After 48hr, 
cells were harvested and treated as in Figure 2A. Viability was measured by ATPlite (mean ± SD; 
n = 3; ****p < 0.0001). 
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Figure 6 
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Figure 6. Mutant p53 sustains ATF6 cleavage and transcriptional activity. 
A) Mutant p53 depletion reduces ATF6 cleavage. MDA-MB-231 cells were silenced for mutp53 
using transient siRNA transfection (sip53 vs siC) or stable shRNA expression (sh-p53 vs empty 
vector). Cells were treated with Tg (1uM) for the indicated times. Western blot experiments were 
performed to detect total (ATF6 tot) and cleaved (ATF6f) forms of ATF6.  
B) Mutant p53 depletion reduces ATF6-dependent transactivation. MDA-MB-231 cells, stably 
transfected with p53 (sh-p53) or control (empty vector) shRNA constructs, were transfected with 
the p5XATF6-GL3 reporter to detect ATF6 transcriptional activity. After 48hr, cells were treated 
with or without Tg (1uM) for the indicated times before processing for dual Luciferase assays 
(mean ± SD; n = 3; **p < 0.01).  
C) Mutant p53 overexpression increases ATF6 cleavage. HBL100 cells were transduced with 
retroviruses encoding mutp53(R280K) or mutp53(R175H). After 48hr, cells were treated with Tg 
(1uM) for the indicated times. Western blot experiments were performed to detect endogenous 
total (ATF6 tot) and cleaved (ATF6 f) forms of ATF6. 
D) ATF6 transcriptional activity is sustained in presence of mutant p53 in basal conditions. The 
indicated cell lines, stably infected with retroviruses encoding p53 (R280K) or p53(R175H), were 
transiently transfected with p5XATF6-GL3 to detect ATF6 transcriptional activity by dual-
Luciferase assays (mean ± SD; n = 3; ***p < 0.001;**p < 0.01). 
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Figure 7 
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Figure 7. Inhibition of ATF6 activity reduces cancer cells viability and invasion.  
A) ATF6 depletion reduces cell viability upon ER stress. MDA-MB-231 cells were transfected with 
ATF6 (siATF6) or control (siC) siRNAs. Cells were treated as in Figure 2A, with viability measured 
by ATP-lite assays (mean ± SD; n = 3; **p < 0.01).  
B) ATF6 depletion affects CHOP and JNK activation by ER stress. MDA-MB-231 were transfected 
as in A and treated with Tg for the indicated times. CHOP mRNA levels were measured by RT-
qPCR. Data are normalized to H3, and compared to untreated cells transfected with siC (mean ± 
SD; n = 3; *p < 0.01). JNK phosphorylation and total protein levels were detected by 
immunoblotting under the same conditions. P53 knockdown was confirmed by western blot. 
HSP90 was blotted as loading control. 
C) ATF6 depletion reduces cancer cells invasion. MDA-MB-231 were transfected as in A and cell 
invasion was measured by matrigel transwell assays. Graphs summarize migrated cells per area 
(mean ± SEM; n=3; ** P<0.01, *** P<0.001). Depletion of endogenous p53 was checked by 
western blot. Representative images of migrated cells, fixed and stained with Crystal Violet  are 
also shown (bottom). 
D) GRP78/BiP is a transcriptional target of ATF6. Cells were transfected with ATF6 (siATF6) or 
control (siC) siRNAs, and treated with Tg or Tm for the indicated times. GRP78 mRNA induction 
upon Tg treatment was measured by RT-qPCR as in A (mean ± SD; n = 3; ***p < 0.001). GRP78 
protein induction upon Tm treatment was analyzed by immunoblotting. ATF6 was blotted to 
confirm efficient depletion. HSP90 was blotted as loading control. 
E) GRP78/BiP induction upon ER stress is reduced in mutant p53-depleted cells. Cells were 
transfected with p53 (sip53) or control (siC) siRNAs, and treated with Tm for 4h. GRP78 mRNA 
induction upon Tg treatment was measured by RT-qPCR (mean ± SD; n = 3; *p < 0.05). GRP78 
protein induction upon Tm treatment was analyzed by immunoblotting. P53 was blotted to 
confirm efficient knockdown. Bottom: the ratio of GRP78 levels compared to HSP90 was 
quantified by densitometry on autoradiography film (mean ± SD; n = 3; ***p < 0.001). 
F) Sec24a expression is reduced upon mutant p53 knockdown. MDA-MB-231 cells were silenced 
for mutant p53 using transient siRNA transfection (sip53 vs siC) and Sec24a mRNA levels were 
detected by RT-qPCR (mean ± SD; n = 6; ****p < 0.0001). Western blot experiments were 
performed to detect sec24a protein in MDA-MB-231 stably depleted of mutant p53 by expression 
of a specific shRNA.  
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Figure 8. ATF6 inhibition reduces cell viability and increases sensitivity to ER stress.  
A) Nelfinavir (NFV) treatment reduces cell survival upon ER stress. MDA-MB-231 cells were 
treated with Tg (1uM), Tm (5ug/ml) or DMSO (vehicle), with or without NFV (25uM). After 48hr 
cell viability was measured by ATPlite assays (mean ± SD; n = 3; ***p < 0.001 **p < 0.01).  
B) NFV inhibits ATF6 cleavage. MB231 cells were transfected with peGFP-ATF6 for 48h, and 
treated with DMSO or NFV for additional 24 h. ATF6 cleavage was detected by GFP 
immunoblotting after 8 hours of Tg treatment. 
C) NFV inhibits ATF6 transcriptional activity. MB231 cells were transfected with p5xATF6-GL3 for 
48hr, and pre-treated with NFV for additional 24hr. ATF6f transcriptional activity was measured 
by dual-Luciferase assay after 8 hours of Tg or Tm treatment (mean ± SD; n = 3; ***p < 0.001). 
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Figure 9. Pharmacological inhibition of mutant p53 increases sensitivity to ER stress. 
A) SAHA treatment reduces cell survival upon ER stress. MDA-MB-231 cells were treated with Tg 
(1uM), Tm (5ug/ml) or DMSO (vehicle), with or without SAHA (5uM). After 48hr cell viability was 
measured by ATPlite assays (mean ± SD; n = 3; ***p < 0.001). 
B) SAHA reduces ATF6 cleavage. Endogenous ATF6 isoforms and mutp53 protein were detected 
by immunoblotting in the absence of drugs. 
C) SAHA inhibits ATF6 transcriptional activity. MB231 cells were transfected with p5xATF6-GL3 
for 48hr, and pre-treated with SAHA for additional 24hr. ATF6f transcriptional activity was 
measured by dual-Luciferase assay after 8 hours of Tg treatment (mean ± SD; n = 3; ***p < 0.001). 
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Figure 10 
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Figure 10. Mutant p53 and ATF6 inhibitors additively sensitize MDA-MB231 cells to ER stress.  
A) Additive effect of SAHA and Nelfinavir (NFV) in reducing cancer cells survival upon ER stress. 
MDA-MB-231 cells were treated for 48 hours with SAHA (5uM), NFV (25uM), Tg (1uM), Tm 
(5ug/ml) or DMSO (vehicle) as indicated. Cell viability was measured by ATP-lite assays (mean ± 
SD; n = 3; ***p < 0.001). 
B) Additive effect of Cerivastatin (CER) and NFV. MDA-MB-231 cells were treated for 48 hours 
with CER (0,1uM or 0,01uM), NFV (25uM), or DMSO (vehicle) as indicated. Cells viability was 
measured by ATP-lite assays (mean ± SD; n = 3; ***p < 0.001). 
C) Viability of non-transformed cells is not reduced by treatment with ATF6 and mutp53 
inhibitors. MCF10A were treated as in B, and cell viability was measured by ATP-lite assays. 
D) The additive effect of Cerivastatin and Nelfinavir is observed in mutp53-bearing MDA-MB-231, 
but not in wtp53-bearing MCF10A. Cells were treated as in B, and viability was measured by ATP-
lite assays. 
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Figure 11. Working model 
Mutant p53 protects cells from ER stress-induced apoptosis by acting at multiple levels. It has 
been shown that mutp53 enhances expression of proteasome subunits, potentially alleviating 
proteotoxic stress (Walerych et al., 2016). It has also been reported that mutp53 controls 
expression of ENTPD5, an enzyme important for N-linked glycosylation and quality control of 
secretory and membrane proteins [2]. In this Thesis, we find that mutp53 acts on multiple 
branches of the UPR. Specifically, pro-apoptotic effectors such as CHOP and JNK are dampened 
in presence of mutant p53, thus reducing cell death. The pro-survival effector ATF6 is activated 
by the presence of mutant p53, favoring ER homeostasis and promoting adaptation to stress. 
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6. Discussion  
In normal and healthy tissue, in response to accumulation of unfolded proteins, cells react by 
activating a transcriptional program known as Unfolded Protein Response (UPR), which first aims 
at restoring homeostasis and resolving stress. However, when stress levels exceed the capability 
of the cells to recover normal conditions, cells undergo apoptosis. In the tumor context, instead, 
cancer cells exposed to the same stress frequently do not activate apoptosis. On the contrary, 
they are more prone to resist, expressing pro-survival effectors and inhibiting pro-apoptotic 
signaling, thus sustaining neoplastic transformation. 
The biological role of the UPR in oncogenesis, cancer development, and resistance to 
chemotherapies is well established (Clarke et al., 2014); however, the specific role of the three 
main UPR sensors, IRE1, PERK, and ATF6, is not so clear. Depending on the duration and 
persistence of stress, all these three receptors could activate both pro-survival and pro-apoptotic 
outcomes. In this context, genetic mutations that support the pro-survival homeostatic functions 
of the UPR are likely to contribute to cancer development and progression – and may also 
become candidate targets for therapy. 
It has been convincingly demonstrated that mutant p53 (mutp53) can act on different crucial 
processes associated with cancer cells’ homeostasis: for instance, by promoting transcription of 
proteasome subunits, or by enhancing ENTDP5 expression, mutp53 has effects on the protein 
degradation and modification machineries, ameliorating the protein landscape of cancer cells 
(Vogiatzi et al., 2016; Walerych et al., 2016). Similarly, by binding and inhibiting DAB2IP, mutant 
p53 is able to enhance activation of survival and metastatic pathways AKT and NF-kB in response 
to inflammatory cytokines or hyperinsulinemia (Di Minin et al., 2014; Valentino et al., 2017). In 
the nucleus, mutant p53 is able to boost basic properties of transcription factors, such as NF-Y, 
SREBP1 and 2 or ETS2, leading to aberrant activation of their downstream programs and 
intersection with other key oncogenic pathways such as YAP/TAZ (Huang et al., 2013; Martinez, 
2016; Sorrentino et al., 2014). Finally, mutant p53 can significantly reprogram the metabolism of 
cancer cells (Zhou et al., 2014), supporting adaptation to the tumor microenvironment. 
Interestingly, analysis of TNBC cell lines with different p53 mutations indicated the Unfolded 
Protein Response as a biological process affected by mutp53 in all lines (Fig 1;Walerych et al., 
2016). This suggested that mutant p53 may exert its oncogenic functions, at least in part, by 
controlling protein folding and by inhibiting UPR-related pro-apoptotic factors, in order to sustain 
cancer cell survival under ER stress conditions. 
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In this Thesis, using metastatic cell lines as model, and inducing ER stress with two different drugs 
(Tm, tunicamycin and Tg, thapsigargin), we uncovered an involvement of mutant p53 in the 
regulation of UPR. Specifically, we demonstrated that mutant p53 promotes cancer cells survival 
upon ER stress, and that mutant p53 depletion dramatically sensitizes cells to ER stress-induced 
apoptosis. 
We also explored the mechanisms by which cells depleted for mutant p53 become more sensitive 
to Tg and Tm treatments, and found that mutant p53 acts by inhibiting IRE1 and PERK activities, 
while it sustains ATF6 functions. 
Notably, IRE1 and PERK control two of the major pro-apoptotic effectors of ER stress, JNK and 
CHOP, so mutant p53, by dampening activation of these receptors, can inhibit apoptosis. In fact, 
we found that induction of DR5, a common target of JNK and CHOP, is important for ER stress-
induced apoptosis upon depletion of mutant p53. Our data confirm that mutant p53 can inhibit 
IRE1 and PERK to alleviate pro-apoptotic responses to ER stress. 
The mechanism by which mutp53 dampens IRE1- and PERK-dependent pro-apoptotic responses 
remains to be defined. We observed that mutp53 depletion increases IRE1 and PERK mRNA and 
protein levels, suggesting that mutant p53 inhibits expression of these receptors. This might in 
part contribute to their reduced activity. However, it is plausible that other actions of mutant 
p53 could be involved in CHOP and JNK inhibition. For instance, mutant p53 interaction with 
DAB2IP – a positive modulator of ASK1 activity – might indirectly impinge on IRE1-mediated JNK 
activation. In fact, DAB2IP has been reported to interact with IRE1 and mediate TRAF2 
recruitment and ASK1/JNK signaling upon ER stress (Luo et al., 2008). In this respect, preliminary 
experiments indicate that Tg-induced early JNK phosphorylation is indeed dampened upon co-
depletion of DAB2IP and mutp53. However, we see no reduction in apoptosis after longer 
treatments (data not shown). These findings may suggest that DAB2IP is important for 
IRE1/TRAF2/ASK1-dependent JNK phosphorylation during early steps of ER stress, but other 
apoptotic mechanisms are activated upon prolonged drug treatments. Additional experiments 
will be required to better define these results. 
Another possibility, is that cytoplasmic mutant p53, which accumulates abundantly in cancer 
cells, might directly interact with UPR sensors such as IRE1 and/or PERK, or their downstream 
effectors, modulating their functions. 
Finally, it is possible that mutant p53 indirectly dampens activation of pro-apoptotic UPR 
effectors, by sustaining the adaptive, homeostatic, and pro-survival activities of ATF6 – de facto 
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reducing ER stress. Indeed, an intriguing observation emerging from loss of function and gain of 
function experiments described in this Thesis is the positive action of mutp53 in sustaining ATF6 
processing and transcriptional activity. 
ATF6 protects cells from chronic stress by activating multiple transcriptional targets (Adachi et 
al., 2008; Wu et al., 2007), and we observed that mutant p53 depletion reduced ATF6 
transcriptional activity. Strikingly, ATF6 depletion – or inhibition – reduced viability and invasion 
of cancer cells. In particular, ATF6 depletion in one hand induced JNK phosphorylation and in the 
other reduced mRNA and protein levels of the ER chaperone GRP78/BiP (official gene symbol 
HSPA5), a key UPR regulator that maintains ER homeostasis, suppresses stress-induced 
apoptosis, and is significantly elevated in malignant cells (Yao et al., 2015). Moreover, we 
observed a reduction in GRP78/BiP mRNA and protein also upon depletion of mutant p53 in our 
cancer cell line model, thus suggesting that mutp53 might increase BiP expression via ATF6. 
Regarding the mechanism by which mutant p53 sustains ATF6 activity, we found that mutant p53 
depletion reduces ATF6 processing to ATF6f, both in basal conditions and upon ER tress. This 
correlates with impaired transactivation of an ATF6-specific reporter and ATF6 target genes such 
as GRP78, suggesting that mutant p53 expression in cancer cells sustains a constant condition of 
ATF6 activation. We hypothesize that mutant p53, by sustaining ATF6, can maintain the status of 
chronic ER stress under the threshold of toxicity, thus protecting cancer cells from apoptosis. 
The biochemical mechanism by which mutp53 promotes ATF6 processing and transcriptional 
activity remains to be defined. One intriguing possibility is that mutant p53 controls ATF6 
transport from the ER to the Golgi. ATF6 needs to be bound by COPII vesicles components sec23 
and sec24 to be translocated to the Golgi apparatus (Schindler and Schekman, 2009), so we 
tested expression of sec24 upon mutp35 depletion. Notably, preliminary results shown a 
reduction in sec24 mRNA and protein levels in the absence of mutant p53, supporting the 
hypothesis that mutp53 might be facilitating ATF6 translocation to the Golgi by upregulating 
components of COPII vesicles. However, we cannot exclude that other mechanisms are involved 
in this process. For instance, mutant p53 could affect the glycosylation pattern of ATF6, since it 
was demonstrated that glycosylation is crucial for ATF6 ER-to-Golgi trafficking (Hong et al., 2004). 
Similarly, it is possible that mutant p53 might increase ER-to-Golgi vesicular trafficking via some 
indirect mechanism, thus promoting a constant delivery of ATF6 to the cis-Golgi even in the 
absence of acute ER stress. Clearly, all these hypotheses await experimental confirmation. 
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Another interesting question regards the possibility that mutant p53-dependent activation of 
ATF6 might induce a specific gene expression profile, with preferential transcription of pro-
survival ATF6 target genes. In fact, current evidence indicates that mutant p53 does not bind 
directly to DNA, but rather interacts with several transcription factors to modify their 
transactivation program. It would be very interesting to test whether ATF6-f binding to target 
promoters is affected by the presence of mutp53, or even if mutp53 might interact with ATF6 to 
sustain transcription of specific target genes. The potential identification of target genes 
regulated by mutant p53 and ATF6, could also give an advantage in better understanding the 
oncogenic role of ATF6. 
The complex interconnections between the three branches of UPR, including the fact that several 
target genes are regulated by the different UPR branches, makes it difficult to define whether 
ATF6 is indeed the key mediator of mutant p53 gain-of-functions in this context. However, we 
wanted to use these novel discoveries to set a strategy for cancer therapy. The idea is to attack 
tumors by targeting several different pro-survival pathways which are used by cancer cells to 
resist to stress during tumor progression. 
In this perspective, ATF6 is an appealing candidate for cancer treatment because of its protective 
role from ER stress, a condition that is chronic in most tumors. ATF6 is required for full induction 
of genes that preserve the protein processing capacity of the ER, and ATF6-depleted cells are 
more sensitive to long term stress (Wu et al., 2007). Our data suggest that mutant p53 sustains 
ATF6 activation to augment the protective functions of UPR, so mutp53-bearing cancer cells 
might be particularly sensitive to ATF6 inhibition. 
In fact, the combination of drugs directly targeting mutant p53 with drugs inhibiting mutant p53-
related pathways (ATF6 or proteasome) is emerging as a promising strategy, as it might favor the 
decrease of compensatory responses and dosage toxicity, and thus an increase in therapeutic 
efficacy. Additional experiments will have to be performed to verify the additive effect of these 
drugs, and test whether they may impact on cancer cell migration and invasion capacities, 
eventually also in in vivo models. 
 
Despite the recent availability of a highly specific ATF6 inhibitor Ceapin-A7 (Gallagher and Walter, 
2016), we have chosen to use Nelfinavir in these experiments, since NFV is already approved for 
clinical use. However, we are aware that NFV acts non-specifically and inhibits various pathways 
in addition to ATF6, so these results need to be carefully considered. 
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Development of less toxic and more bio-available versions of Ceapins is currently ongoing at the 
Walter laboratory (UCSF), and amelioration of these molecules may represent an optimal 
strategy to improve specificity of treatments. 
 
In conclusion, TP53 is one of the most frequently mutated genes in human cancer and is emerging 
as a major oncoprotein which controls a multitude of tumor-promoting activities. Therefore, not 
only mutant p53 itself but also its many downstream pathways and cooperators, represent 
important potential drug targets. We have uncovered a novel functional axis that links mutant 
p53 to the UPR, and may contribute to protect cancer cells from basal or therapy-induced ER 
stress. Targeting this axis could provide an additional opportunity for treatment. 
 
 
 
 
 
 
 
  
59 
 
7. Experimental Procedures 
 
Cell Culture. H1299 were cultured in RPMI medium (Sigma) supplemented with 10% FBS 
(ECS0180L, Euroclone), and antibiotics (ECB3001D, Euroclone). MDA-MB-231, MEF and HBL-100 
were cultured in DMEM medium (Sigma) supplemented with 10% FBS, and antibiotics.  SUM-
159PT cells were maintained in DMEM:F12 Ham’s medium 1:1, supplemented with 10% FBS. All 
human cell lines were subjected to STR genotyping with PowerPlex 18D System and confirmed in 
their identity comparing the results to reference cell databases (DMSZ, ATCC, and JCRB 
databases). MEFs were generated by crossing mice of the appropriate genotype, and collecting 
cells from 13.5 d.p.c. embryos. MEF p53KO and MEF KI p53R172H were immortalized through 
retroviral transduction of H-RasV12 (Girardini et al., 2011). 
Transfections, plasmids and siRNAs. Plasmid transfections were performed using Lipofectamine® 
LTX with Plus™ Reagent (ThermoFisher), following manufacturer’s instructions. 24 hours post 
transfection, cells were washed with PBS for two times and new fresh culture medium was 
added. p5xATF6-GL3 and peGFP-ATF6 were purchased from Addgene (#11976, #32955). pLPC-
p53R175H and pLPC-p53R280K were obtained by cloning respectively p53R175H and p53R280K 
coding region into pLPC empty vector. pLPCp53*R175H and -p53*R280K were generated 
introducing silent mutations in the region targeted by p53 siRNA by site directed mutagenesis in 
pLPC-p53R175H and -p53R280K respectively. pSR-shp53 plasmid was generated by cloning in the 
pRS retroviral vector a double stranded oligo corresponding to sip53-ORF (described above). 
For siRNA transfections, cells were plated and transfected the day after with 50 nM siRNA 
oligonucleotides using Lipofectamine RNAiMax (Invitrogen), following manufacturer’s 
instructions. After 48 hours of silencing, cells were processed. 
siRNAs, used in this Thesis are listed in the following table: 
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Viral Transduction. For Retrovirus and Lentivirus production HEK-293GP and HEK-293T cells were 
transfected with the packaging plasmids and the plasmid construct of interest, using standard 
calcium-phosphate method or Fugene reagent (Promega), respectively. After 8 hours, medium 
was changed and cells were incubated at 37°C. After 48 hours, the supernatants containing viral 
particles were filtered (0.45 μm filter), supplemented with 10% FBS and polybrene (8ug/ml). The 
culture medium of target cells growing at low confluence (≈30-40%) was replaced by the 
appropriate viral supernatant and incubated at 37°C for 24 hours. Cells were selected with 
puromycin (0,5 μg/ml) and kept under selection for the entire experiment.  
Treatments. Thapsigargin (Tg) was purchased from Sigma (T9033) and dissolved in DMSO. Cells 
were treated with Tg [1uM ] for the indicated times. Tunicamycin ( Tm ) was purchased from 
Sigma (T7765) and dissolved in DMSO. Cells were treated with Tm [5 ug/ml] for the indicated 
times. IRE1 inhibitor (STF-083010) was purchased from Calbiochem (412510) and dissolved in 
DMSO. Cells were treated with IREi [60uM] for 48hours. PERK inhibitor (GSK-2606414) was 
purchased from Tocris (PF 429242) and dissolved in Ethanol. Cells were treated with PERKi [100 
uM] for 48 hours. Nelfinavir mesylate hydrate (NFV) was purchased from Sigma (PZ0013) and 
siRNA Sequence Purchase from/  References 
Control 
siRNA (siC) 
Unknown All star negative control 
(1027281, Qiagen) 
SiRNA p53 GACUCCAGUGGUAAUCUAC Eurofins MWG 
siRNA ATF6 
(smart pool) 
1.CAUGAGAAAUGUCGGUUCA 
2.GGAGGCACCUUCUAGGAUU 
3.GAGGAUGGGUUCAUAGACA 
4.UGGAUGAAGUUGUGUCAGA 
 
Darmacon 
siRNA CHOP AAGGAAGUGUAUCUUCAUA Eurofins MWG 
siRNA JNK AGAAGGUAGGACAUUCUUU Eurofins MWG 
siRNA DR5 AUGAGAUAAAGGUGGCUAA Eurofins MWG 
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dissolved in DMSO. Cells were treated with NFV [25uM] for 48 hours. Ceapins-A7 were a gift from 
Peter Walter’s lab and dissolved in DMSO. Cells were treated with Ceapins-A7 [5uM] for 48hours. 
SAHA was purchased from CAYMAN (149647-78-9) and dissolved in DMSO. Cells were treated 
with SAHA [5uM] for 48 hours. Cerivastatin (CER) was purchased from Sigma (SML0005) and 
dissolved in DMSO. Cells were treated with two doses [0,1uM] and [0,001uM] for 48 hours. 
Cell manipulation and Western blot analysis. Total cell extracts were prepared in RIPA buffer 
without SDS (150mM NaCl, 50mM Tris-HCl pH8, 1mM EDTA, 1% NP-40, 0.5% Na-deoxycholate) 
supplemented with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 10µg/ml CLAP, 1µM TSA and 5µM 
nicotinamide. Protein concentration was determined with Bio-Rad Protein Assay Reagent (#500-
0006, Bio-Rad). Lysates were resolved by SDS/PAGE and transferred to nitrocellulose (Millipore). 
Western blot analysis were performed according to standard procedures using the following 
primary antibodies.  
Antibody Diluition Purchase from/ References 
Anti-ATF6 1:1000 Abcam (ab 122897) 
Anti-PERK 1:4000 Cell signaling (#3192) 
Anti-IRE1a 1:2000 Cell signaling (#3294) 
Anti-pJNK 1:500 Cell signaling (#9251) 
Anti- pan JNK  1:1000 Cell signaling (#9252) 
Anti-DO1 1:8000 Santa cruz (sc-126) 
Anti-PARP p85 fragment 1:1000 TB273 (Promega) 
Anti-GRP78 1:8000 GeneTex (GTX113340) 
Anti-actin  1:1000  Sigma (#A9718) 
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Anti-mouse and anti-rabbit HRPO-conjugated (Sigma), were used as secondary antibodies. 
RNA extraction and RT-qPCR. Total RNA was extracted with QIAzol (Qiagen) following 
manufacturer’s instructions. For mRNA expression analysis, 5ug of total RNA were reverse-
transcribed with QuantiTect Reverse Transcription (Qiagen). Analyzed genes were amplified 
using SsoAdvancedTMSYBR® Green Master Mix (Biorad) on a CFX96™ Real-Time PCR System 
(Biorad).  
List of primers used: 
Anti-GFP 1:1000 home-made rabbit polyclonal 
HSP90  1:5000 sc-13119 (Santa Cruz) 
Target Primers 
H3 Fw: 5’GAAGAAACCTCATCGTTACAGGCCTGGT3’ 
Rw: 5’CTGCAAAGCACCAATAGCTGCACTCTGGAA 3’ 
IRE 1 Fw: 5'- ACGCCCACTCTGTATGTTGG -3' 
Rw: 5'- CAAACTTGACGTCCGTGCTG -3' 
PERK Fw: 5'- ATCCCCCATGGAACGACCTG -3' 
Rw: 5'- ACCCGCCAGGGACAAAAATG -3' 
ATF6 Fw: 5'- TGAACTTCGAGGATGGGTTG -3' 
Rw: 5'- TCACTCCCTGAGTTCCTGCT -3' 
XBP1s Fw: 5'- TGCTGAGTCCGCAGCAGGTG -3' 
Rw: 5'- GCTGGCAGGCTCTGGGGAAG -3' 
CHOP Fw: 5'- CAGAACCAGCAGAGGTCACA -3' 
Rw: 5'- AGCTGTGCCACTTTCCTTTC -3' 
GRP78 Fw: 5'- TGTTCAACCAATTATCAGCAAACTC -3' 
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Cell viability assay and FACS analysis.  For cell viability assay, we used ATP-lite Luminescence 
Assay System (PerkinElmer, 6016943). Cells were plated in 96 well for 24 hours before further 
treatments. ATPlite reactions were done according to manufacturer instructions, and measured 
using an Enspire plate-reader.  
For FACS analysis, adherent and floating cells were harvested, permeabilized with 0.1% NP-40 in 
PBS containing RNase A (200 μg/ml) and then stained with 50 μg/ml Propidium Iodide (#P4865, 
Sigma). At least 2x104 cells were counted in each experiment, using a FACSCalibur flow cytometer 
(Becton-Dickinson). Cell cycle analysis was performed with FlowJo software 
(http://www.flowjo.com/).  
Luciferase assay. Luciferase assays were performed using p5xATF6-GL3, bearing five repetitions 
of a specific binding sequence for ATF6-f. Luciferase reporters were transfected together with 
CMV-Renilla to normalize for transfection efficiency. Luciferase was measured on a Promega 
luminometer. For luciferase assays in siRNA-transfected cells, cells were first transfected with the 
indicated siRNAs and, after 24 h, washed from transfection media, transfected with plasmid DNA, 
and collected 24 h later. 
Statistical Analysis.  In all graphs data are expressed as mean ± SD of three independent 
experiments, except when otherwise indicated. Differences were analyzed by Student’s t test 
using Prism 6 (GraphPad), except when otherwise indicated. P-values < 0.05 were considered 
significant. 
 
 
 
 
  
Rw: 5'- TTCTGCTGTATCCTCTTCACCAGT -3' 
DR5 Fw: 5’ - CTCTCTCAGGCATCATCATAGG - 3’ 
Rw: 5'-GCAAGATACTCACGATCTCATT-3 
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